Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2023	Feb. 29, 2024	Jun. 30, 2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	000-55435
Entity Registrant Name	SILA REALTY TRUST, INC.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	46-1854011
Entity Address, Address Line One	1001 Water Street
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33602
City Area Code	813
Local Phone Number	287-0101
Title of 12(b) Security	None
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Documents Incorporated by Reference	Portions of Registrant’s proxy statement for the 2024 annual stockholders meeting, to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2023, are incorporated by reference in Part III. Items 10, 11, 12, 13 and 14.
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001567925
No Trading Symbol Flag	true
Class A
Entity Public Float			$ 1,371,507,000
Entity Common Stock, Shares Outstanding (in shares)		169,361,000
Class I
Entity Public Float			137,112,000
Entity Common Stock, Shares Outstanding (in shares)		17,019,000
Class T
Entity Public Float			336,623,000
Entity Common Stock, Shares Outstanding (in shares)		41,891,000
Class T2
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding (in shares)		0

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Tampa, Florida

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Real estate:
Land	$ 157,821	$ 163,419
Buildings and improvements, less accumulated depreciation of $227,156 and $209,118, respectively	1,470,831	1,716,663
Total real estate, net	1,628,652	1,880,082
Cash and cash equivalents	202,019	12,917
Intangible assets, less accumulated amortization of $102,456 and $90,239, respectively	134,999	167,483
Goodwill	17,700	21,710
Right-of-use assets	36,384	37,443
Other assets	79,825	100,167
Total assets	2,099,579	2,219,802
Liabilities:
Credit facility, net of deferred financing costs of $1,847 and $2,412, respectively	523,153	580,588
Accounts payable and other liabilities	30,381	30,619
Intangible liabilities, less accumulated amortization of $7,417 and $5,923, respectively	10,452	11,946
Lease liabilities	41,158	41,554
Total liabilities	605,144	664,707
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 100,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.01 par value per share, 510,000,000 shares authorized; 244,617,615 and 241,425,332 shares issued, respectively; 227,934,254 and 226,255,969 shares outstanding, respectively	2,279	2,263
Additional paid-in capital	2,042,741	2,024,176
Distributions in excess of accumulated earnings	(567,188)	(499,334)
Accumulated other comprehensive income	16,603	27,990
Total stockholders’ equity	1,494,435	1,555,095
Total liabilities and stockholders’ equity	$ 2,099,579	$ 2,219,802

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Buildings and improvements, accumulated depreciation	$ 227,156	$ 209,118
Intangible assets, accumulated amortization	102,456	90,239
Credit facility, deferred financing costs	1,847	2,412
Intangible liabilities, accumulated amortization	$ 7,417	$ 5,923
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	510,000,000	510,000,000
Common stock, shares issued (in shares)	244,617,615	241,425,332
Common stock, shares outstanding (in shares)	227,934,254	226,255,969

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Rental revenue	$ 189,065	$ 179,986	$ 172,838
Expenses:
Rental expenses	20,196	17,950	17,712
General and administrative expenses	23,896	22,079	21,388
Depreciation and amortization	74,293	77,199	70,259
Impairment losses	24,252	47,424	27,837
Total operating expenses	142,637	164,652	137,196
Gain on real estate dispositions	22	460	89
Interest and other income	702	305	3,110
Interest expense	23,110	24,077	37,625
Income (loss) from continuing operations	24,042	(7,978)	1,216
Income from discontinued operations	0	0	401,444
Net income (loss) attributable to common stockholders	24,042	(7,978)	402,660
Other comprehensive (loss) income - unrealized (loss) gain on interest rate swaps, net	(11,387)	32,837	15,597
Comprehensive income attributable to common stockholders	$ 12,655	$ 24,859	$ 418,257
Weighted average number of common shares outstanding:
Basic (in shares)	227,199,543	225,320,043	223,325,293
Diluted (in shares)	229,046,546	225,320,043	224,293,339
Basic:
Continuing operations (in dollars per share)	$ 0.11	$ (0.03)	$ 0
Discontinued operations, (in dollars per share)	0	0	1.80
Net income (loss) attributable to common stockholders, (in dollars per share)	0.11	(0.03)	1.80
Diluted:
Continuing operations (in dollars per share)	0.10	(0.03)	0
Discontinued operations (in dollars per share)	0	0	1.79
Net income (loss) attributable to common stockholders, (in dollars per share)	$ 0.10	$ (0.03)	$ 1.79

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Distributions in Excess of Accumulated Earnings	Accumulated Other Comprehensive Income (Loss)
Balance, (in shares) at Dec. 31, 2020		222,045,522
Balance beginning at Dec. 31, 2020	$ 1,653,873	$ 2,220	$ 1,983,361	$ (311,264)	$ (20,444)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)		3,243,363
Issuance of common stock under the distribution reinvestment plan	27,584	$ 33	27,551
Vesting of restricted stock (in shares)		24,955
Stock-based compensation	2,379		2,379
Distribution and servicing fees	639		639
Other offering costs	(9)		(9)
Repurchase of common stock (in shares)		(1,133,901)
Repurchase of common stock	(9,528)	$ (11)	(9,517)
Distributions to common stockholders	(492,065)			(492,065)
Other comprehensive income (loss)	15,597				15,597
Net income (loss)	402,660			402,660
Balance, (in shares) at Dec. 31, 2021		224,179,939
Balance ending at Dec. 31, 2021	1,601,130	$ 2,242	2,004,404	(400,669)	(4,847)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)		3,026,326
Issuance of common stock under the distribution reinvestment plan	24,834	$ 30	24,804
Vesting of restricted stock (in shares)		172,887
Stock-based compensation	4,180	$ 2	4,178
Other offering costs	(4)		(4)
Repurchase of common stock (in shares)		(1,123,183)
Repurchase of common stock	(9,217)	$ (11)	(9,206)
Distributions to common stockholders	(90,687)			(90,687)
Other comprehensive income (loss)	32,837				32,837
Net income (loss)	$ (7,978)			(7,978)
Balance, (in shares) at Dec. 31, 2022	226,255,969	226,255,969
Balance ending at Dec. 31, 2022	$ 1,555,095	$ 2,263	2,024,176	(499,334)	27,990
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)		3,031,829
Issuance of common stock under the distribution reinvestment plan	24,751	$ 30	24,721
Vesting of restricted stock (in shares)		160,453
Stock-based compensation	6,284	$ 1	6,283
Other offering costs	(80)		(80)
Repurchase of common stock (in shares)		(1,513,997)
Repurchase of common stock	(12,374)	$ (15)	(12,359)
Distributions to common stockholders	(91,896)			(91,896)
Other comprehensive income (loss)	(11,387)				(11,387)
Net income (loss)	$ 24,042			24,042
Balance, (in shares) at Dec. 31, 2023	227,934,254	227,934,254
Balance ending at Dec. 31, 2023	$ 1,494,435	$ 2,279	$ 2,042,741	$ (567,188)	$ 16,603

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss) attributable to common stockholders	$ 24,042	$ (7,978)	$ 402,660
Adjustments to reconcile net income (loss) attributable to common stockholders to net cash provided by operating activities:
Depreciation and amortization	74,293	77,199	82,018
Amortization of deferred financing costs	1,665	1,679	3,425
Amortization of above- and below-market leases	733	484	(1,098)
Other amortization expenses	794	2,302	3,269
Gain on real estate dispositions from continuing operations	(22)	(460)	(89)
Gain on real estate dispositions of discontinued operations	0	0	(395,801)
Loss on extinguishment of debt	0	3,367	28,751
Impairment losses	24,252	47,424	27,837
Straight-line rent adjustments, net of write-offs	(2,197)	(7,261)	(15,665)
Stock-based compensation	6,284	4,180	2,379
Changes in operating assets and liabilities:
Accounts payable and other liabilities	26	(170)	(4,521)
Other assets	(946)	909	3,777
Net cash provided by operating activities	128,924	121,675	136,942
Cash flows from investing activities:
Investments in real estate	(69,822)	(157,194)	(71,462)
Consideration paid for the internalization transaction	0	0	(15,000)
Proceeds from real estate dispositions and related notes receivable	270,306	22,822	1,338,709
Capital expenditures and other costs	(3,177)	(8,440)	(25,405)
Net cash provided by (used in) investing activities	197,307	(142,812)	1,226,842
Cash flows from financing activities:
Payments on notes payable	0	0	(453,422)
Proceeds from credit facility	50,000	845,000	15,000
Payments on credit facility	(108,000)	(762,000)	(453,000)
Payments for extinguishment of debt	0	(4)	(29,244)
Payments of deferred financing costs	(193)	(6,937)	(444)
Repurchase of common stock	(12,374)	(9,217)	(9,528)
Offering costs on issuance of common stock	(47)	(192)	(2,326)
Distributions to common stockholders	(66,515)	(65,310)	(465,849)
Net cash (used in) provided by financing activities	(137,129)	1,340	(1,398,813)
Net change in cash, cash equivalents and restricted cash	189,102	(19,797)	(35,029)
Cash, cash equivalents and restricted cash - Beginning of year	13,083	32,880	67,909
Cash, cash equivalents and restricted cash - End of year	202,185	13,083	32,880
Supplemental cash flow disclosure:
Interest paid, net of interest capitalized of $0, $44 and $395, respectively	21,671	17,361	38,558
Supplemental disclosure of non-cash transactions:
Common stock issued through distribution reinvestment plan	24,751	24,834	27,584
Change in accrued distributions to common stockholders	630	543	(1,368)
Change in accounts payable and other liabilities related to capital expenditures and investments in real estate	(1,332)	(3,705)	(243)
Right-of-use assets obtained in exchange for new lease liabilities	$ 0	$ 15,305	$ 625

CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Cash Flows [Abstract]
Interest capitalized	$ 0	$ 44	$ 395

Organization and Business Operations	12 Months Ended
Organization and Business Operations	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Organization and Business Operations Sila Realty Trust, Inc., or the Company, is a Maryland corporation, headquartered in Tampa, Florida, that has elected, and currently qualifies, to be taxed as a real estate investment trust, or a REIT, under the Internal Revenue Code of 1986, as amended, or the Code, for federal income tax purposes. The Company is primarily focused on investing in high quality healthcare assets across the continuum of care, which the Company believes typically generate predictable, durable and growing income streams. The Company may also make other real estate-related investments, which may include equity or debt interests in other real estate entities. Substantially all of the Company’s business is conducted through Sila Realty Operating Partnership, LP, a Delaware limited partnership, or the Operating Partnership. The Company is the sole general partner of the Operating Partnership and directly and indirectly owns 100% of the Operating Partnership. Except as the context otherwise requires, the “Company” refers to Sila Realty Trust, Inc., the Operating Partnership and their wholly-owned subsidiaries.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and the accompanying notes thereto are the responsibility of management. These accounting policies conform to U.S. generally accepted accounting principles, or GAAP, in all material respects, and have been consistently applied in preparing the consolidated financial statements.

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company, the Operating Partnership, and their wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements and accompanying notes in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

Cash consists of demand deposits at commercial banks. Cash equivalents consist of highly liquid investments in money market funds with original maturities of three months or less at the time of purchase. Restricted cash consists of cash held in an escrow account in accordance with a tenant's lease agreement. Restricted cash is reported in other assets in the accompanying consolidated balance sheets. The Company maintains its cash, cash equivalents and restricted cash at various financial institutions. As of December 31, 2023, certain of the Company’s cash deposits exceeded federally insured amounts. To date, the Company has experienced no loss or lack of access to cash in its accounts. The Company attempts to limit cash investments to financial institutions with high credit standing; therefore, the Company believes it is not exposed to any significant credit risk on its cash deposits.

The following table presents a reconciliation of the beginning of year and end of year cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the totals shown in the consolidated statements of cash flows (amounts in thousands):


	Year Ended December 31,
	2023		2022		2021
Beginning of year:
Cash and cash equivalents	$	12,917	$	32,359	$	53,174
Restricted cash	166		521		14,735
Cash, cash equivalents and restricted cash	$	13,083	$	32,880	$	67,909

End of year:
Cash and cash equivalents	$	202,019	$	12,917	$	32,359
Restricted cash	166		166		521
Cash, cash equivalents and restricted cash	$	202,185	$	13,083	$	32,880

Investment in Real Estate

Real estate costs related to the acquisition, development, construction and improvement of properties are capitalized. Repair and maintenance costs are expensed as incurred, and significant replacements and improvements are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate assets. The Company considers the period of future benefit of an asset in determining the appropriate useful life. Real estate assets, other than land, are depreciated on a straight-line basis over each asset’s useful life. The Company anticipates the estimated useful lives of its assets by class as follows:


Buildings and improvements						15 – 40 years
Tenant improvements						Shorter of lease term or expected useful life
Furniture, fixtures, and equipment						3 – 10 years

Allocation of Purchase Price of Real Estate

Upon the acquisition of real estate properties, the Company evaluates whether the acquisition is a business combination or an asset acquisition. For both business combinations and asset acquisitions, the Company allocates the purchase price of properties to acquired tangible assets, consisting of land, buildings and improvements, and intangible assets and liabilities, consisting of the value of above-market and below-market leases and the value of in-place leases. For asset acquisitions, the Company capitalizes transaction costs and allocates the purchase price using a relative fair value method allocating all accumulated costs. For business combinations, the Company expenses transaction costs incurred and allocates the purchase price based on the estimated fair value of each separately identifiable asset and liability. For the year ended December 31, 2023, all of the Company's acquisitions were determined to be asset acquisitions.

The fair value of the tangible assets of an acquired property (which includes land, buildings and improvements) is determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land and buildings and improvements based on management’s determination of the relative fair value of these assets.

The amount allocated to in-place leases includes an estimate of direct costs associated with obtaining a new tenant and opportunity costs associated with lost rentals that are avoided by acquiring an in-place lease. These lease intangibles are amortized to depreciation and amortization expense over the remaining terms of the respective leases. If a lease is terminated prior to its stated expiration, all unamortized amounts of in-place lease assets relating to that lease would be expensed.

The amounts allocated to above-market and below-market leases are recorded based on the present value of the difference between: (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) an estimate of current market lease rates for the corresponding leases, measured over a period equal to the remaining non-cancelable term of the lease including any fixed rate bargain renewal periods, with respect to a below-market lease. These above-market and below-market amounts are amortized as an adjustment of rental revenue over the remaining terms of the respective leases. If a lease is terminated prior to its stated expiration, all unamortized amounts of above-market and below-market lease values related to that lease would be recorded as an adjustment to rental revenue.

Held for Sale

The Company classifies a real estate property as held for sale upon satisfaction of all of the following criteria: (i) management commits to a plan to sell the property; (ii) the property is available for immediate sale in its present condition, subject only to terms that are usual and customary for sales of such properties; (iii) there is an active program to locate a buyer; (iv) the sale of the property is probable and transfer of the asset is expected to be completed within one year; (v) the property is being actively marketed for sale; and (vi) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.

Upon the determination to classify a property as held for sale, the Company ceases depreciation and amortization on the real estate property held for sale, as well as the amortization of any related intangible assets. Such properties are recorded at the lesser of the carrying value or estimated fair value less estimated costs to sell.

Impairments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate assets may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate assets may not be recoverable, the Company assesses the recoverability of the asset group by estimating undiscounted future cash flows, including eventual disposition. Based on this analysis, if the Company does not believe that it will be able to recover the carrying value of the asset group, an impairment charge will be recorded to the extent that the carrying value exceeds the estimated fair value of the asset group.

When developing estimates of expected future cash flows, the Company makes certain assumptions regarding future market rental rates subsequent to the expiration of current lease arrangements, property operating expenses, terminal capitalization and discount rates, probability weighting of potential uses of the property, sale prices of comparable properties, required tenant improvements and the number of years the property will be held for investment. The use of alternative assumptions in the future cash flow analysis could result in a different determination of the property’s future cash flows and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate assets.

In addition, the Company determines fair value by using a direct capitalization method, a discounted cash flow method using the assumptions noted above, or by utilizing comparable market information based on the view of a market participant. The use of alternative assumptions in these approaches could result in a different determination of the property’s estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate assets.

The Company accounts for goodwill in accordance with Accounting Standards Codification, or ASC, 350, Intangibles - Goodwill and Other, and allocates its goodwill to its reporting units, which have been determined to be at the individual property level. Goodwill has an indefinite life and is not amortized.

The Company evaluates goodwill for impairment at least annually, as of the last day of each year, or upon the occurrence of a triggering event. A triggering event is an event or circumstance that would more-likely-than-not indicate that the fair value of a reporting unit is below its carrying value.

The Company has the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. Under a qualitative assessment, the impairment analysis for goodwill represents an evaluation of whether it is more-likely-than-not the reporting unit's fair value is less than its carrying value, including goodwill. If a qualitative analysis indicates that it is more-likely-than-not that the estimated carrying value of a reporting unit, including goodwill, exceeds its fair value, the Company performs the quantitative analysis. The quantitative analysis consists of estimating the fair value of each reporting unit using discounted projected future cash flows and comparing those estimated fair values with the carrying values, which include the allocated goodwill. If the estimated fair value is less than the carrying value, the Company would then recognize a goodwill impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to that reporting unit.

Deferred Financing Costs

Deferred financing costs are loan fees, legal fees and other third-party costs associated with obtaining and further modifying financing. These costs are amortized over the terms of the respective financing agreements using the effective interest method. Deferred financing costs related to the term loan portion of the credit facility are recorded as a reduction of the related debt on the accompanying consolidated balance sheets. Deferred financing costs related to the revolving line of credit are recorded in other assets in the accompanying consolidated balance sheets.

Fair Value

ASC 820, Fair Value Measurements and Disclosures, or ASC 820, defines fair value, establishes a framework for measuring fair value in accordance with GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is intended to be a market-based measurement, as opposed to a transaction-specific measurement.

Fair value is defined by ASC 820 as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate the fair value. Assets and liabilities are measured using inputs from three levels of the fair value hierarchy, as follows:

Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market is defined as a market in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2—Inputs other than quoted prices for similar assets and liabilities in active markets that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs).

Level 3—Unobservable inputs, only used to the extent that observable inputs are not available, reflect the Company’s assumptions about the pricing of an asset or liability.

Revenue Recognition and Tenant Receivables

The majority of the Company's revenue is derived from rental revenue, which is accounted for in accordance with ASC 842, Leases, or ASC 842. Under ASC 842, rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). For lease arrangements where it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. Differences between rental revenue recognized and amounts contractually due under the lease agreements are credited or charged to straight-line rent receivable. Tenant reimbursements, which are comprised of additional amounts recoverable from tenants for common area maintenance expenses and certain other recoverable expenses, are recognized when the services are provided and the performance obligations are satisfied.

Share Repurchase Program

The Company’s Amended and Restated Share Repurchase Program, or the SRP, allows for repurchases of shares of the Company’s common stock upon meeting certain criteria. The SRP provides that all repurchases during any calendar year, including those redeemable upon death or a "Qualifying Disability" (as defined in the Company's SRP) of a stockholder, be limited to those that can be funded with equivalent proceeds raised from the Company's distribution reinvestment plan, or DRIP, during the prior calendar year and other operating funds, if any, as the Company's board of directors, or the Board, in its sole discretion, may reserve for this purpose.

Repurchases of shares of the Company’s common stock are at the sole discretion of the Board, provided, however, that the Company limits the number of shares repurchased during any calendar year to 5.0% of the total number of shares of common stock outstanding as of December 31st of the previous calendar year. The SRP is subject to terms and limitations, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation and DRIP funding limitations and any amendments to the plan. In addition, the Board, in its sole discretion, may suspend (in whole or in part) the SRP at any time, and may amend, reduce, terminate or otherwise change the SRP upon 30 days' prior notice to the Company’s stockholders for any reason it deems appropriate.

The Company will currently only repurchase shares due to death and involuntary exigent circumstances in accordance with the SRP, subject in each case to the terms and limitations of the SRP. Under the SRP, the Company may waive certain of the terms and requirements of the SRP in the event of the death of a stockholder who is a natural person, including shares held through an Individual Retirement Account or other retirement or profit-sharing plan, and certain trusts meeting the requirements of the SRP. The Company may also waive certain of the terms and requirements of the SRP in the event of an involuntary exigent circumstance, as determined by the Company or any of the executive officers thereof, in its or their sole discretion.

Distribution Policy

In order to maintain its status as a REIT, the Company is required to make distributions each taxable year equal to at least 90% of its REIT taxable income, computed without regard to the dividends paid deduction and excluding capital gains. To the extent funds are available, the Company intends to continue to pay regular distributions to stockholders. Distributions are paid to stockholders of record as of the applicable record dates. Distributions to stockholders are determined by the Board and are dependent upon a number of factors, including funds available for the payment of distributions, financial condition, the timing

of property acquisitions, capital expenditure requirements, and annual distribution requirements in order to maintain the Company’s status as a REIT.

Stock-based Compensation

On March 6, 2020, the Board approved the Amended and Restated 2014 Restricted Share Plan, or the A&R Incentive Plan, pursuant to which the Company has the authority and power to grant awards of restricted shares of its Class A common stock to its directors, officers and employees. The Company accounts for its stock awards in accordance with ASC 718-10, Compensation—Stock Compensation. ASC 718-10 requires that compensation cost for all stock awards be calculated and amortized over the service period (generally equal to the vesting period). For performance-based awards, compensation costs are recognized over the service period if it is probable that the performance condition will be satisfied, with changes of the assessment at each reporting period and recording the effect of the change in the compensation cost as a cumulative catch-up adjustment. The compensation costs for restricted stock are recognized based on the fair value of the restricted stock awards at grant date. Forfeitures are accounted for as they occur.

Earnings Per Share

The Company calculates basic earnings per share by dividing net income (loss) attributable to common stockholders for the period by the weighted average shares of its common stock outstanding for that period. All classes of common stock are allocated net income (loss) attributable to common stockholders at the same rate per share and receive the same gross distribution per share. Diluted earnings per share is computed based on the weighted average number of shares outstanding and all potentially dilutive securities. Shares of non-vested restricted common stock and performance-based deferred stock unit awards, or Performance DSUs, are considered to be participating securities because they contain non-forfeitable rights to distributions and give rise to potentially dilutive shares of common stock.

Reportable Segments

ASC 280, Segment Reporting, establishes standards for reporting financial and descriptive information about an entity’s reportable segments. As of December 31, 2023 and December 31, 2022, all of the Company's consolidated revenues were generated from real estate investments in healthcare properties. The Company’s chief operating decision maker evaluates operating performance of healthcare properties on an individual property level, which are aggregated into one operating segment due to their similar economic characteristics. The aggregated operating segment is the Company's only reportable segment.

Derivative Instruments and Hedging Activities

As required by ASC 815, Derivatives and Hedging, or ASC 815, the Company records all derivative instruments at fair value as assets and liabilities on its consolidated balance sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.

In accordance with the fair value measurement guidance in Accounting Standards Update, or ASU, 2011-04, Fair Value Measurement, the Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

The Company is exposed to variability in expected future cash flows that are attributable to interest rate changes in the normal course of business. The Company’s primary strategy in entering into derivative contracts is to add stability to future cash flows by managing its exposure to interest rate fluctuations. The Company utilizes derivative instruments, including interest rate swaps, to effectively convert its variable rate debt to fixed rate debt. The Company does not enter into derivative instruments for speculative purposes.

In accordance with ASC 815, the Company designates interest rate swap contracts as cash flow hedges of floating-rate borrowings. For derivative instruments that are designated and qualify as cash flow hedges, the gains or losses on the derivative instruments are reported as other comprehensive (loss) income - unrealized (loss) gain on interest rate swaps, net in the consolidated statements of comprehensive income and are reclassified into earnings in the same line item associated with the forecasted transaction in the same period during which the hedged transactions affect earnings.

Income Taxes

The Company currently qualifies and is taxed as a REIT under Sections 856 through 860 of the Code. Accordingly, it will generally not be subject to corporate U.S. federal or state income tax to the extent that it makes qualifying distributions to stockholders, and provided it satisfies, on a continuing basis, through actual investment and operating results, the REIT requirements, including certain asset, income, distribution and stock ownership tests. If the Company fails to qualify as a REIT,

it would be subject to U.S. federal, state and local income taxes and may be precluded from qualifying as a REIT for the subsequent four taxable years following the year in which it lost its REIT qualification, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Accordingly, failure to qualify as a REIT could have a material adverse impact on the results of operations and amounts available for distribution to stockholders.

The dividends paid deduction of a REIT for qualifying dividends paid to its stockholders is computed using the Company’s taxable income as opposed to net income reported in the consolidated financial statements. Taxable income, generally, will differ from net income reported in the consolidated financial statements because the determination of taxable income is based on tax provisions and not financial accounting principles.

The Company has concluded that there was no impact related to uncertain tax positions from results of operations of the Company for the years ended December 31, 2023, 2022 and 2021. The earliest tax year currently subject to examination is 2020.

Recently Issued Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is evaluating the disclosure requirements of ASU 2023-07 and does not anticipate that this update will have a material impact on its consolidated financial statements.

Real Estate

12 Months Ended

Dec. 31, 2023

Real Estate [Abstract]

Real Estate Investments

Real Estate

Acquisitions

During the year ended December 31, 2023, the Company purchased two real estate properties in two separate transactions, which were determined to be asset acquisitions. The Company allocated the purchase price to tangible assets, consisting of land, building and improvements and tenant improvements, and intangible assets, consisting of in-place leases, based on the relative fair value method of allocating all accumulated costs.

The following table summarizes the consideration transferred and the purchase price allocation for acquisitions during the year ended December 31, 2023 (amounts in thousands):


Property Description	Date Acquired	Ownership Percentage	Consideration Transferred (amount in thousands)
West Palm Beach Healthcare Facility	06/15/2023	100%	$	9,920
Burr Ridge Healthcare Facility	09/27/2023	100%	59,902



Total			$	69,822


	Total
Land	$	6,892
Building and improvements	51,337
Tenant improvements	1,826
In-place leases	9,767

Total assets acquired	$	69,822

The Company capitalized acquisition costs of approximately $158,000, which are included in the allocation of the real estate acquisitions presented above.

Dispositions

During the year ended December 31, 2023, the Company sold three real estate properties for $271,107,000, generating net proceeds of $270,306,000.

Investment Risk Concentrations

As of December 31, 2023, the Company had one exposure to geographic concentration that accounted for at least 10.0% of rental revenue for the year ended December 31, 2023. Real estate properties located in the Houston-Pasadena-The Woodlands, Texas metropolitan statistical area accounted for 10.2% of rental revenue for the year ended December 31, 2023.

As of December 31, 2023, the Company had one exposure to tenant concentration that accounted for at least 10.0% of rental revenue for the year ended December 31, 2023. The leases with tenants at properties under the common control of Post Acute Medical, LLC and its affiliates accounted for 14.5% of rental revenue for the year ended December 31, 2023.

Impairment Losses

The Company recorded impairment losses on real estate of $24,252,000 (including goodwill impairments of $4,010,000), for the year ended December 31, 2023, as a result of property sales and tenant related triggering events that occurred at certain properties. In addition, during the year ended December 31, 2023, the Company recorded an impairment of in-place lease and above-market lease intangible assets of $1,130,000 and $260,000, respectively. The fair values of these properties were determined based on the guidance in ASC 820. These impairments were allocated to the asset groups, for each respective property, on a pro-rata basis, which included land, buildings and improvements, and their related intangible assets.

During the year ended December 31, 2022, the Company recorded impairment losses on real estate of $47,424,000 (including goodwill impairments of $1,574,000). In addition, during the year ended December 31, 2022, the Company recorded an impairment of an in-place lease intangible asset of $4,345,000.

During the year ended December 31, 2021, the Company recorded impairment losses on real estate of $27,837,000 (including goodwill impairments of $671,000). The impaired properties related to the 2021 impairments were all subsequently sold.

Impairment losses on real estate (including goodwill impairments) are recorded as impairment losses in the accompanying consolidated statements of comprehensive income. Impairments of in-place leases are included in depreciation and amortization in the accompanying consolidated statements of comprehensive income. Impairments of above-market leases are recorded as a reduction to rental revenue in the accompanying consolidated statements of comprehensive income.

The following table summarizes the rollforward of goodwill for the years ended December 31, 2023 and 2022 (amounts in thousands):


	Year Ended December 31,
	2023		2022
Balance at beginning of year	$	21,710	$	23,284
Impairment losses	(4,010)		(1,574)
Balance at end of year	$	17,700	$	21,710

Discontinued Operations

12 Months Ended

Dec. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

The Company formerly invested in data center properties and during the second quarter of 2021, the Board made a determination to sell the Company's data center properties. On May 19, 2021, the Company and certain of its wholly-owned subsidiaries entered into a purchase and sale agreement, or the PSA, for the sale of 29 data center properties owned by the Company, which constituted the entirety of the Company's data center segment. The decision of the Board to sell the data center properties, as well as the execution of the PSA, represented a strategic shift that had a major effect on the Company's results and operations. On July 22, 2021, the Company completed the sale of its data center segment, or the Data Center Sale, for an aggregate sale price of $1,320,000,000, and generated net proceeds of approximately $1,295,367,000. Concurrently, the Board declared a special cash distribution of $1.75 per share of Class A, Class I, Class T and Class T2 shares of common stock. The special cash distribution was funded with the proceeds from the Data Center Sale. The special cash distribution was paid on

July 30, 2021 to stockholders of record at the close of business on July 26, 2021, in an aggregate amount of approximately $392,685,000.

The operations reflected in income from discontinued operations (which consisted solely of the Company's former data center segment) on the consolidated statements of comprehensive income for the year ended December 31, 2021, were as follows (amounts in thousands):


	Year Ended December 31,
		2021
Revenue:
Rental revenue		$	57,903
Lease termination revenue		7,075
Total revenue		64,978
Expenses:
Rental expenses		15,737



Depreciation and amortization		11,759


Total expenses		27,496
Interest and other expense, net (1)		31,839
Income from discontinued operations		5,643
Gain on real estate dispositions		395,801
Net income from discontinued operations attributable to common stockholders		$	401,444

(1) Interest expense attributable to discontinued operations for the year ended December 31, 2021 was $31,856,000, which related to notes payable on certain data center properties. On July 22, 2021, in connection with the Data Center Sale, the Company paid off all data center and healthcare related notes payable, with an outstanding principal balance of $450,806,000 at the time of repayment and incurred approximately $23,738,000 of debt extinguishment costs related to the data center properties.

Capital expenditures on a cash basis for the year ended December 31, 2021, was $2,763,000, related to properties classified within discontinued operations.

There were no significant non-cash operating or investing activities for the properties classified within discontinued operations for the year ended December 31, 2021.

Intangible Assets, Net

12 Months Ended

Dec. 31, 2023

Finite-Lived Intangible Assets, Net [Abstract]

Intangible Assets, Net

Intangible assets, net, consisted of the following as of December 31, 2023 and 2022 (amounts in thousands, except weighted average remaining life amounts):


	December 31, 2023		December 31, 2022
In-place leases, net of accumulated amortization of $95,325 and $83,788, respectively (with a weighted average remaining life of 7.8 years and 8.9 years, respectively)	$	125,188	$	155,365
Above-market leases, net of accumulated amortization of $7,131 and $6,451, respectively (with a weighted average remaining life of 6.7 years and 7.9 years, respectively)	9,811		12,118
	$	134,999	$	167,483

The aggregate weighted average remaining life of the intangible assets was 7.7 years and 8.8 years as of December 31, 2023 and 2022, respectively.

Amortization of intangible assets was $23,766,000, $27,389,000 and $23,157,000 for the years ended December 31, 2023, 2022, and 2021, respectively. Amortization of in-place leases is included in depreciation and amortization, and amortization of above-market leases is recorded as an adjustment to rental revenue in the accompanying consolidated statements of comprehensive income.

Estimated amortization expense on the intangible assets as of December 31, 2023, for each of the next five years ending December 31 and thereafter, is as follows (amounts in thousands):


Year	Amount
2024	$	20,351
2025	18,362
2026	16,815
2027	15,238
2028	13,704
Thereafter	50,529
	$	134,999

Intangible Liabilities, Net

12 Months Ended

Dec. 31, 2023

Intangible Lease Liabilities, Net [Abstract]

Intangible Liabilities, Net

Intangible liabilities, net, consisted of the following as of December 31, 2023 and 2022 (amounts in thousands, except weighted average remaining life amounts):


	December 31, 2023		December 31, 2022
Below-market leases, net of accumulated amortization of $7,417 and $5,923, respectively (with a weighted average remaining life of 7.4 years and 8.4 years, respectively)	$	10,452	$	11,946

Amortization of below-market leases was $1,494,000, $1,479,000 and $1,322,000 for the years ended December 31, 2023, 2022, and 2021 respectively. Amortization of below-market leases is recorded as an adjustment to rental revenue in the accompanying consolidated statements of comprehensive income.

Estimated amortization of the intangible liabilities as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


Year	Amount
2024	$	1,494
2025	1,494
2026	1,475
2027	1,450
2028	1,146
Thereafter	3,393
	$	10,452

Leases

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Leases

Lessor

The Company’s real estate properties are leased to tenants under operating leases with varying terms. Typically, the leases have provisions to extend the terms of the lease agreements. The Company retains substantially all of the risks and benefits of ownership of the real estate properties leased to tenants.

Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31, and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	177,637
2025	173,816
2026	168,143
2027	165,189
2028	160,868
Thereafter	829,692
Total	$	1,675,345

Lessee

The Company is subject to various non-cancellable operating lease agreements on which certain of its properties reside and for its corporate offices.

The Company's operating leases do not provide implicit interest rates. In order to calculate the present value of the remaining operating lease payments, the Company used incremental borrowing rates, or IBRs, adjusted for a number of factors. The determination of an appropriate IBR involves multiple inputs and judgments. The Company determined its IBRs considering the general economic environment, term of the underlying leases, and various financing and asset specific adjustments to ensure the IBRs are appropriate for the intended use of the underlying operating leases.

The effects of the Company's leases are recorded in right-of-use assets and lease liabilities on the consolidated balance sheets.

The future rent payments, discounted by the Company's IBRs, under non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	2,746
2025	2,768
2026	2,715
2027	2,681
2028	2,692
Thereafter	104,764
Total undiscounted rental payments	118,366
Less imputed interest	(77,208)
Total lease liabilities	$	41,158
Weighted average IBR	5.5		%
Weighted average remaining lease term	36.5 years

The following table provides details of the Company's total lease costs for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


		Year Ended December 31,
	Location in Consolidated Statements of Comprehensive Income		2023		2022		2021
Operating lease costs:
Ground lease costs (1)	Rental expenses		$	2,727	$	2,246	$	1,846
Ground lease costs (2)	Income from discontinued operations		—		—		414
Corporate operating lease costs	General and administrative expenses		735		741		1,129
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases			$	732	$	531	$	1,067

(1)The Company receives reimbursements from tenants for certain operating ground leases, which are recorded as rental revenue in the accompanying consolidated statements of comprehensive income.

(2)Amount relates to lease costs attributable to operating ground leases related to data center properties disposed of in the Data Center Sale on July 22, 2021.

Leases

Lessor

The Company’s real estate properties are leased to tenants under operating leases with varying terms. Typically, the leases have provisions to extend the terms of the lease agreements. The Company retains substantially all of the risks and benefits of ownership of the real estate properties leased to tenants.

Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31, and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	177,637
2025	173,816
2026	168,143
2027	165,189
2028	160,868
Thereafter	829,692
Total	$	1,675,345

Lessee

The Company is subject to various non-cancellable operating lease agreements on which certain of its properties reside and for its corporate offices.

The Company's operating leases do not provide implicit interest rates. In order to calculate the present value of the remaining operating lease payments, the Company used incremental borrowing rates, or IBRs, adjusted for a number of factors. The determination of an appropriate IBR involves multiple inputs and judgments. The Company determined its IBRs considering the general economic environment, term of the underlying leases, and various financing and asset specific adjustments to ensure the IBRs are appropriate for the intended use of the underlying operating leases.

The effects of the Company's leases are recorded in right-of-use assets and lease liabilities on the consolidated balance sheets.

The future rent payments, discounted by the Company's IBRs, under non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	2,746
2025	2,768
2026	2,715
2027	2,681
2028	2,692
Thereafter	104,764
Total undiscounted rental payments	118,366
Less imputed interest	(77,208)
Total lease liabilities	$	41,158
Weighted average IBR	5.5		%
Weighted average remaining lease term	36.5 years

The following table provides details of the Company's total lease costs for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


		Year Ended December 31,
	Location in Consolidated Statements of Comprehensive Income		2023		2022		2021
Operating lease costs:
Ground lease costs (1)	Rental expenses		$	2,727	$	2,246	$	1,846
Ground lease costs (2)	Income from discontinued operations		—		—		414
Corporate operating lease costs	General and administrative expenses		735		741		1,129
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases			$	732	$	531	$	1,067

(1)The Company receives reimbursements from tenants for certain operating ground leases, which are recorded as rental revenue in the accompanying consolidated statements of comprehensive income.

(2)Amount relates to lease costs attributable to operating ground leases related to data center properties disposed of in the Data Center Sale on July 22, 2021.

Other Assets

12 Months Ended

Dec. 31, 2023

Other Assets [Abstract]

Other Assets

Other assets consisted of the following as of December 31, 2023 and 2022 (amounts in thousands):


	December 31, 2023		December 31, 2022
Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $1,917 and $889, respectively	$	2,271	$	3,178
Leasing commissions, net of accumulated amortization of $191 and $167, respectively	593		775

Restricted cash	166		166
Tenant receivables	2,398		1,736
Straight-line rent receivable	53,248		62,457

Prepaid and other assets	4,089		3,865
Derivative assets	17,060		27,990
	$	79,825	$	100,167

Amortization of deferred financing costs related to the revolver portion of the credit facility for the years ended December 31, 2023, 2022, and 2021 was $1,027,000, $1,087,000, and $1,430,000, respectively, which was recorded as interest expense, in the accompanying consolidated statements of comprehensive income.

Accounts Payable and Other Liabilities

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accounts Payable and Other Liabilities

Accounts payable and other liabilities consisted of the following as of December 31, 2023 and 2022 (amounts in thousands):


	December 31, 2023		December 31, 2022
Accounts payable and accrued expenses	$	3,906	$	5,387
Accrued interest expense	1,714		1,941
Accrued property taxes	3,687		2,421
Accrued personnel costs	4,425		3,940

Distributions payable to stockholders	7,782		7,719
Performance DSUs distributions payable	1,140		573
Tenant deposits	877		877
Deferred rental income	6,393		7,761
Derivative liabilities	457		—

	$	30,381	$	30,619

Credit Facility

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Credit Facility

The Company's outstanding credit facility as of December 31, 2023 and 2022 consisted of the following (amounts in thousands):


	Weighted Average Contractual Rate(1)	December 31, 2023		December 31, 2022

Variable rate revolving line of credit	—%	$	—	$	8,000
Variable rate term loans fixed through interest rate swaps	3.28%	525,000		485,000
Variable rate term loans	—%	—		90,000
Total credit facility, principal amount outstanding	3.28%	525,000		583,000
Unamortized deferred financing costs related to credit facility term loans		(1,847)		(2,412)
Total credit facility, net of deferred financing costs		$	523,153	$	580,588

(1)Weighted average contractual rate is as of December 31, 2023.

Significant activities regarding the credit facility during the year ended December 31, 2023 include:

•On February 17, 2023, the Company entered into an interest rate swap agreement to hedge $40,000,000 of its variable rate term loans with an effective date of March 1, 2023.

•On March 8, 2023, the Company repaid $8,000,000 on its revolving line of credit with cash flows from operations.

•On April 13, 2023, the Company repaid $10,000,000 on its 2024 term loan with proceeds from a disposition and cash flows from operations.

•On July 13, 2023, the Company repaid $10,000,000 on its 2024 term loan with proceeds from the collection of a note receivable related to a disposition and cash flows from operations.

•On September 26, 2023, the Company drew $50,000,000 on its revolving line of credit to fund an acquisition.

•On November 1, 2023, the Company repaid $8,000,000 on its revolving line of credit with cash flows from operations and proceeds from a disposition.

•On December 8, 2023, the Company, the Operating Partnership, and Truist Bank amended the credit facility to address the calculation of pool availability, including (i) removing the implied debt service coverage ratio restriction which reduces the impact of market interest rate volatility on the Company’s ability to access commitments available, (ii) removing the ground lease concentration limitation, and (iii) amending the credit facility from a borrowing base calculation to an unencumbered pool structure, including the addition of an unsecured interest coverage ratio requirement.

•On December 19, 2023, the Company repaid $42,000,000 on its revolving line of credit and $30,000,000 on its 2024 term loan with proceeds from a disposition.

The principal payments due on the credit facility as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


	Amount
2024 (1)	$	250,000
2025	—
2026	—
2027	—
2028	275,000
Thereafter	—
	$	525,000

(1)The 2024 term loan has a maturity date of December 31, 2024, and, at the Company's election, may be extended for a period of six-months on no more than two occasions, subject to the satisfaction of certain conditions, including the payment of an extension fee. The Company currently meets these conditions and therefore may choose to exercise its option to extend the maturity date of the 2024 term loan.

As of December 31, 2023, the maximum commitments available under the revolving line of credit were $500,000,000, which may be increased, subject to lender approval, through incremental term loans and/or revolving loan commitments in an aggregate amount not to exceed $1,000,000,000. As of December 31, 2023, the maximum commitments available under the 2024 Term Loan were $250,000,000, which may be increased, subject to lender approval, to an aggregate amount not to exceed $550,000,000. As of December 31, 2023, the maximum commitments available under the 2028 Term Loan Agreement were $275,000,000, which may be increased, subject to lender approval, to an aggregate amount not to exceed $500,000,000.

At the Company’s election, loans under the credit facility may be made as Base Rate Loans or Secured Overnight Financing Rate, or SOFR, Loans. The applicable margin for loans that are Base Rate Loans is adjustable based on a total leverage ratio, ranging from 0.25% to 0.90%. The applicable margin for loans that are SOFR Loans is adjustable based on a total leverage ratio, ranging from 1.25% to 1.90%.

In addition to interest, the Company is required to pay a fee on the unused portion of the lenders’ commitments under the revolving line of credit at a rate per annum equal to 0.20% if the average daily amount outstanding under the revolving line of credit is less than 50% of the aggregate commitments, or 0.15% if the average daily amount outstanding under the revolving line of credit is equal to or greater than 50% of the aggregate commitments. The unused fee is payable quarterly in arrears and recorded as interest expense in the accompanying consolidated statements of comprehensive income.

The revolving line of credit contains customary financial and operating covenants, including covenants relating to a maximum consolidated leverage ratio, maximum secured leverage ratio, fixed charge coverage ratio, unsecured interest coverage ratio, minimum consolidated tangible net worth, maximum distribution/payout ratio, covenants restricting the issuance of debt, imposition of liens, and entering into affiliate transactions.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Fair Value

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Fair Value

Cash and cash equivalents, restricted cash, tenant receivables, prepaid and other assets, accounts payable and other liabilities—The Company considers the carrying values of these financial instruments, assets and liabilities, to approximate fair value because of the short period of time between origination of the instruments and their expected realization.

Credit facility—The outstanding principal of the credit facility was $525,000,000 and $583,000,000, which approximated its fair value due to the variable nature of the terms as of December 31, 2023 and 2022, respectively.

The fair value of the Company's credit facility is estimated based on the interest rates currently offered to the Company by its financial institutions.

Derivative instruments—The Company’s derivative instruments consist of interest rate swaps. These swaps are carried at fair value to comply with the provisions of ASC 820. The fair value of these instruments is determined using interest rate market pricing models. The Company incorporated credit valuation adjustments to appropriately reflect the Company’s nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. The Company determined that the majority of the inputs used to value its interest rate swaps fall within Level 2 of the fair value hierarchy. The credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by the Company and the respective counterparty. However, as of December 31, 2023, the Company assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and determined that the credit valuation adjustments are not significant to the overall valuation of its interest rate swaps. As a result, the Company determined that its interest rate swaps valuation in its entirety is classified in Level 2 of the fair value hierarchy.

Considerable judgment is necessary to develop estimated fair values of financial assets and liabilities. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize or be liable for on disposition of the financial assets and liabilities.

The following tables show the fair value of the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (amounts in thousands):


	December 31, 2023
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets:
Derivative assets	$	—	$	17,060	$	—	$	17,060
Total assets at fair value	$	—	$	17,060	$	—	$	17,060
Liabilities:
Derivative liabilities	$	—	$	457	$	—	$	457
Total liabilities at fair value	$	—	$	457	$	—	$	457


	December 31, 2022
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets:
Derivative assets	$	—	$	27,990	$	—	$	27,990
Total assets at fair value	$	—	$	27,990	$	—	$	27,990

Derivative assets and liabilities are reported in the consolidated balance sheets as other assets and accounts payable and other liabilities, respectively.

Real Estate Assets—Certain real estate assets (which include land, buildings and improvements and intangible assets) were adjusted to fair value as a result of impairments which occurred during the year ended December 31, 2023. The fair values of real estate assets were determined by using either third-party purchase offers, the direct capitalization method or comparable sales information. The fair values of real estate assets based on third-party purchase offers are reflected in the Level 2 fair value hierarchy. The direct capitalization method is based on applying a capitalization rate to the estimated market rental income to be generated by the property. The comparable sales technique uses estimates of properties similar to the subject property by comparing prices per square foot considering recent transaction activity. The estimates of comparable sales and prices per square foot have been adjusted, and are considered significant inputs and thus are classified within Level 3 of the fair value hierarchy.

The following table shows the fair value of the Company's real estate assets, including intangible assets (at fair value measured on a non-recurring basis on the date of impairment), which the Company continues to own, as of December 31, 2023 (amounts in thousands):


	December 31, 2023
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2) (1)		Significant Unobservable Inputs (Level 3)		Total Fair Value		Total Losses (2)
Real estate assets	$	—	$	21,400	$	16,200	$	37,600	$	20,758

(1)Amount includes $1,400,000 attributable to a real estate asset that was adjusted to fair value on December 31, 2022, which the Company continues to own as of December 31, 2023. The Company recorded total losses of $29,010,000 for this real estate asset during the year ended December 31, 2022.

(2)Amount represents losses recorded during 2023 and includes impairments of in-place lease intangible assets of $1,130,000, and real estate assets of $19,628,000 (including goodwill impairments of $792,000).

The following table sets forth quantitative information about the significant unobservable inputs of the Company’s Level 3 real estate recorded as of December 31, 2023:


Significant Unobservable Inputs	December 31, 2023
Overall capitalization rate	8.5%
Market rent per square foot	$45.00
Range of comparable sale price per square foot	$	60.86	-	$	98.04

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Derivative Instruments and Hedging Activities

12 Months Ended

Dec. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy.

For derivatives designated and qualifying as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest is incurred on the Company’s variable rate debt. During the next twelve months, the Company estimates that an additional $14,114,000 will be reclassified from accumulated other comprehensive income as a reduction to interest expense.

The following table summarizes the notional amount and fair value of the Company’s derivative instruments (amounts in thousands):


Derivatives Designated as Hedging Instruments	Balance Sheet Location	Effective Dates	Maturity Dates	December 31, 2023						December 31, 2022
				Outstanding Notional Amount		Fair Value of				Outstanding Notional Amount		Fair Value of
						Assets		(Liabilities)				Assets

Interest rate swaps	(1)	05/01/2022 to 05/01/2023	12/31/2024 to 01/31/2028	$	525,000	$	17,060	$	(457)	$	485,000	$	27,990

(1) Derivative assets and liabilities are reported in the consolidated balance sheets as other assets and accounts payable and other liabilities, respectively.

The notional amount under the agreements is an indication of the extent of the Company’s involvement in each instrument at the time, but does not represent exposure to credit, interest rate or market risks.

The table below summarizes the amount of income and loss recognized on the interest rate derivatives designated as cash flow hedges for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


Derivatives in Cash Flow Hedging Relationships	Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives		Location of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)	Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)		Total Amount of Line Item in Consolidated Statements of Comprehensive Income







Year Ended December 31, 2023
Interest rate swaps	$	5,293	Interest expense	$	16,680	$	23,110


Year Ended December 31, 2022
Interest rate swaps	$	32,317	Interest expense	$	(520)	$	24,077


Year Ended December 31, 2021
Interest rate swaps - continuing operations	$	5,956	Interest expense	$	(8,031)	$	37,625
Interest rate swaps - discontinued operations	(37)		Income from discontinued operations	(1,647)		401,444
Total	$	5,919		$	(9,678)

Credit Risk-Related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations. The Company records credit risk valuation adjustments on its interest rate swaps based on the respective credit quality of the Company and the counterparty. The Company believes it mitigates its credit risk by entering into agreements with creditworthy counterparties. As of December 31, 2023, the Company had no derivatives with fair value in a net liability position, inclusive of accrued interest but excluding any adjustment for nonperformance risk related to the agreement. As of December 31, 2023, there were no termination events or events of default related to the interest rate swaps.

Tabular Disclosure Offsetting Derivatives

The Company has elected not to offset derivative positions in its consolidated financial statements. The following tables present the effect on the Company’s financial position had the Company made the election to offset its derivative positions as of December 31, 2023 and December 31, 2022 (amounts in thousands):


Offsetting of Derivative Assets
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets Presented in the Balance Sheet		Financial Instruments Collateral		Cash Collateral		Net Amount
December 31, 2023	$	17,060	$	—	$	17,060	$	(457)	$	—	$	16,603
December 31, 2022	$	27,990	$	—	$	27,990	$	—	$	—	$	27,990


Offsetting of Derivative Liabilities
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Liabilities Presented in the Balance Sheet		Financial Instruments Collateral		Cash Collateral		Net Amount
December 31, 2023	$	457	$	—	$	457	$	(457)	$	—	$	—

Stockholders' Equity

12 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Distributions Paid and Distributions Payable

The Company declared distributions per share of common stock in the amounts of $0.40, $0.40 and $2.19 for the years ended December 31, 2023, 2022 and 2021, respectively. The distributions declared for the year ended December 31, 2021, includes a special cash distribution of $1.75 per share of Class A, Class I, Class T and Class T2 shares of common stock. The special cash distribution was funded with the proceeds from the Data Center Sale. The special cash distribution was paid on July 30, 2021 to stockholders of record at the close of business on July 26, 2021. As of December 31, 2023, the Company had distributions payable of approximately $7,782,000. Of these distributions payable, approximately $5,729,000 was paid in cash and approximately $2,053,000 was reinvested in shares of common stock pursuant to the DRIP on January 8, 2024.

Share Repurchase Program

The Company’s Amended and Restated Share Repurchase Program allows for repurchases of shares of the Company’s common stock upon meeting certain criteria. During the year ended December 31, 2023, the Company repurchased 1,513,997 Class A shares, Class I shares and Class T shares of common stock (1,182,006 Class A shares, 105,660 Class I shares and 226,331 Class T shares), or 0.67% of shares outstanding as of December 31, 2022, for an aggregate purchase price of approximately $12,374,000 (an average of $8.17 per share). During the year ended December 31, 2022, the Company repurchased 1,123,183 Class A shares, Class I shares and Class T shares of common stock (981,772 Class A shares, 31,666 Class I shares and 109,745 Class T shares), or 0.50% of shares outstanding as of December 31, 2021, for an aggregate purchase price of approximately $9,217,000 (an average of $8.21 per share).

Accumulated Other Comprehensive Income

The following table presents a rollforward of amounts recognized in accumulated other comprehensive income by component for the years ended December 31, 2023, 2022, and 2021 (amounts in thousands):


	Unrealized Income (Loss) on Derivative Instruments
Balance as of December 31, 2020	$	(20,444)
Other comprehensive income before reclassification	5,919
Amount of loss reclassified from accumulated other comprehensive loss to net income	9,678
Other comprehensive income	15,597
Balance as of December 31, 2021	$	(4,847)
Other comprehensive income before reclassification	32,317
Amount of loss reclassified from accumulated other comprehensive loss to net loss	520
Other comprehensive income	32,837
Balance as of December 31, 2022	$	27,990
Other comprehensive income before reclassification	5,293
Amount of income reclassified from accumulated other comprehensive income to net income	(16,680)
Other comprehensive loss	(11,387)
Balance as of December 31, 2023	$	16,603

The following table presents reclassifications out of accumulated other comprehensive income for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


Details about Accumulated Other Comprehensive Income Components	(Income) Loss Amounts Reclassified from Accumulated Other Comprehensive Income to Net Income (Loss)						Affected Line Items in the Consolidated Statements of Comprehensive Income
	Year Ended December 31,
	2023		2022		2021
Interest rate swap contracts - continuing operations	$	(16,680)	$	520	$	8,031	Interest expense
Interest rate swap contracts - discontinued operations	—		—		1,647		Income from discontinued operations
Interest rate swap contracts	$	(16,680)	$	520	$	9,678

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Earnings Per Share	12 Months Ended
Earnings Per Share	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per ShareThe Company calculates basic earnings per share by dividing net income (loss) attributable to common stockholders for the period by the weighted average shares of its common stock outstanding for that period. All classes of common stock are allocated net income (loss) attributable to common stockholders at the same rate per share and receive the same gross distribution per share. Diluted earnings per share is computed based on the weighted average number of shares outstanding and all potentially dilutive securities. Shares of non-vested restricted common stock and performance-based deferred stock unit awards, or Performance DSUs, are considered to be participating securities because they contain non-forfeitable rights to distributions and give rise to potentially dilutive shares of common stock. For the year ended December 31, 2023, diluted earnings per share reflected the effect of approximately 1,847,000 non-vested shares of restricted common stock and Performance DSUs that were outstanding. For the year ended December 31, 2022, diluted earnings per share was computed the same as basic earnings per share because the Company recorded a loss from continuing operations, which would make potentially dilutive shares of 1,341,000 related to non-vested shares of restricted common stock and Performance DSUs, anti-dilutive. For the year ended December 31, 2021, diluted earnings per share reflected the effect of approximately 968,000 non-vested shares of restricted common stock and Performance DSUs that were outstanding.

Stock-based Compensation

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

The Board has authorized a total of 5,000,000 Class A shares of common stock for issuance under the A&R Incentive Plan on a fully diluted basis at any time. Subject to certain limited exceptions, restricted stock may not be sold, assigned, transferred, pledged, encumbered, hypothecated or otherwise disposed of and is subject to forfeiture within the vesting period.

The Company recognized total stock-based compensation expense of $6,284,000, $4,180,000, and $2,379,000 respectively, for the years ended December 31, 2023, 2022, and 2021. Stock-based compensation expense is reported in general and administrative expenses in the accompanying consolidated statements of comprehensive income, and forfeitures are recorded as they occur.

As of December 31, 2023 and 2022, there was $6,807,000 and $6,834,000, respectively, of total unrecognized compensation expense related to nonvested shares of the Company’s restricted Class A common stock and Performance DSUs. This expense is expected to be recognized over a remaining weighted average period of 1.94 years. This expected expense does not include the impact of any future stock-based compensation awards.

The fair value of each restricted stock and Performance DSU award is estimated based on the most recent Estimated Per Share NAV. As of December 31, 2023 and 2022, the fair value of the nonvested shares of restricted Class A common stock and Performance DSUs was $15,098,000 and $11,703,000, respectively. The following table summarizes restricted Class A common stock activity, including Performance DSUs, for the year ended December 31, 2023:


						Shares
Nonvested at December 31, 2022						1,423,690
Granted						793,718
Vested						(160,453)
Forfeited						(38,451)
Nonvested at December 31, 2023						2,018,504

Income Taxes

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

As a REIT, the Company generally will not be subject to U.S. federal income tax on taxable income that it distributes to the stockholders. For U.S. federal income tax purposes, distributions to stockholders are characterized as either ordinary dividends, capital gain distributions, or nontaxable distributions. Nontaxable distributions will reduce U.S. stockholders’ respective bases in their shares. The following table shows the character of distributions the Company paid on a percentage basis during the years ended December 31, 2023, 2022 and 2021:


	Year Ended December 31,
Character of Distributions (1):	2023		2022		2021
Ordinary dividends	61.41	%	40.94	%	27.91	%
Capital gain distributions	—	%	—	%	—	%
Nontaxable distributions	38.59	%	59.06	%	72.09	%
Total	100.00	%	100.00	%	100.00	%

	Year Ended December 31,
Character of Special Distribution (1):	2023		2022		2021
Ordinary dividends	—	%	—	%	12.39	%
Capital gain distributions	—	%	—	%	86.66	%
Nontaxable distributions	—	%	—	%	0.95	%
Total	—	%	—	%	100.00	%

(1)Attributable to Class A shares, Class I shares, Class T shares of common stock for the year ended December 31, 2023. Attributable to Class A shares, Class I shares, Class T shares, and Class T2 shares of common stock for the years ended December 31, 2022 and 2021.

The Company applies the rules under ASC 740-10, Accounting for Uncertainty in Income Taxes, for uncertain tax positions using a “more likely than not” recognition threshold for tax positions. Pursuant to these rules, the financial statement effects of a tax position are initially recognized when it is more likely than not, based on the technical merits of the tax position, that such a position will be sustained upon examination by the relevant tax authorities. If the tax benefit meets the “more likely than not” threshold, the measurement of the tax benefit will be based on the Company's estimate of the ultimate tax benefit to be sustained if audited by the taxing authority. The Company concluded there was no impact related to uncertain tax positions

from the results of the operations of the Company for the years ended December 31, 2023, 2022 and 2021. The earliest tax year currently subject to examination is 2020.

The Company’s policy is to recognize accrued interest related to unrecognized tax benefits as a component of interest expense and penalties related to unrecognized tax benefits as a component of general and administrative expenses. From inception through December 31, 2023, the Company has not recognized any interest expense or penalties related to unrecognized tax benefits.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings In the ordinary course of business, the Company may become subject to litigation or claims. As of December 31, 2023, there were, and currently there are, no material pending legal proceedings to which the Company is a party. While the resolution of a lawsuit or proceeding may have an impact to the Company's financial results for the period in which it is resolved, the Company believes that the final resolution of the lawsuits or proceedings in which it is currently involved, either individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or liquidity.

Subsequent Events

12 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Distributions Paid to Stockholders

The following table summarizes the Company's distributions paid to stockholders on January 8, 2024, for the period from December 1, 2023 through December 31, 2023 (amounts in thousands):


Payment Date	Common Stock	Cash		DRIP		Total Distribution
January 8, 2024	Class A	$	4,597	$	1,190	$	5,787
January 8, 2024	Class I	347		229		576
January 8, 2024	Class T	785		634		1,419

		$	5,729	$	2,053	$	7,782

The following table summarizes the Company's distributions paid to stockholders on February 7, 2024, for the period from January 1, 2024 through January 31, 2024 (amounts in thousands):


Payment Date	Common Stock	Cash		DRIP		Total Distribution
February 7, 2024	Class A	$	4,600	$	1,181	$	5,781
February 7, 2024	Class I	347		229		576
February 7, 2024	Class T	786		632		1,418

		$	5,733	$	2,042	$	7,775

Distributions Authorized

The following tables summarize the daily distributions approved and authorized by the Board subsequent to December 31, 2023:


Authorization Date (1)	Common Stock	Daily Distribution Rate (1)		Annualized Distribution Per Share
January 15, 2024	Class A	$	0.00109290	$	0.40
January 15, 2024	Class I	$	0.00109290	$	0.40
January 15, 2024	Class T	$	0.00109290	$	0.40


Authorization Date (2)	Common Stock	Daily Distribution Rate (2)		Annualized Distribution Per Share
February 15, 2024	Class A	$	0.00109290	$	0.40
February 15, 2024	Class I	$	0.00109290	$	0.40
February 15, 2024	Class T	$	0.00109290	$	0.40


Authorization Date (3)	Common Stock	Daily Distribution Rate (3)		Annualized Distribution Per Share
March 5, 2024	Class A	$	0.00109290	$	0.40
March 5, 2024	Class I	$	0.00109290	$	0.40
March 5, 2024	Class T	$	0.00109290	$	0.40

(1)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on February 1, 2024 and ending on February 29, 2024. The distributions are calculated based on 366 days in the calendar year. The distributions declared for each record date in February 2024 will be paid in March 2024. The distributions are payable to stockholders from legally available funds therefor.

(2)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on March 1, 2024 and ending on March 31, 2024. The distributions will be calculated based on 366 days in the calendar year. The distributions declared for each record date in March 2024 will be paid in April 2024. The distributions will be payable to stockholders from legally available funds therefor.

(3)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on April 1, 2024 and ending on April 30, 2024. The distributions will be calculated based on 366 days in the calendar year. The distributions declared for each record date in April 2024 will be paid in May 2024. The distributions will be payable to stockholders from legally available funds therefor.

Disposition of New Bedford Healthcare Facility

On January 31, 2024, the Company sold the New Bedford Healthcare Facility for $1,500,000, generating net proceeds of $1,407,000, after transaction costs and other prorations, subject to additional transaction costs paid subsequent to the closing date.

Acquisition of Brownsburg Healthcare Facility

On February 26, 2024, the Company purchased 100% of the ownership interests in a healthcare property in Brownsburg, Indiana, or the Brownsburg Healthcare Facility, for a contract purchase price of $39,063,000.

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

12 Months Ended

Dec. 31, 2023

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

SCHEDULE III — REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

December 31, 2023

(in thousands)


					Initial Cost				Cost Capitalized Subsequent to Acquisition (b)		Gross Amount Carried at December 31, 2023
Property Description	Location	Encumbrances			Land		Buildings and Improvements				Land		Buildings and Improvements (c)		Total		Accumulated Depreciation (d)		Year Constructed	Year Renovated	Date Acquired
Houston Healthcare Facility	Houston, TX	$	—	(a)	$	762	$	2,970	$	106	$	762	$	3,076	$	3,838	$	960	1993	—	07/31/2014
Cincinnati Healthcare Facility	Cincinnati, OH	—		(a)	356		3,167		114		356		3,281		3,637		907		2001	—	10/29/2014
Winston-Salem Healthcare Facility	Winston-Salem, NC	—		(a)	684		4,903		—		684		4,903		5,587		1,322		2004	—	12/17/2014
Stoughton Healthcare Facility	Stoughton, MA	—		(a)	4,049		19,991		(13,054)		2,018		8,968		10,986		—		1973	1997	12/23/2014
Fort Worth Healthcare Facility	Fort Worth, TX	—		(a)	8,297		35,615		—		8,297		35,615		43,912		8,443		2014	—	12/31/2014
Fort Worth Healthcare Facility II	Fort Worth, TX	—		(a)	367		1,587		201		367		1,788		2,155		665		2014	—	12/31/2014
Winter Haven Healthcare Facility	Winter Haven, FL	—		(a)	—		2,805		—		—		2,805		2,805		697		2009	—	01/27/2015
Overland Park Healthcare Facility	Overland Park, KS	—		(a)	1,558		20,549		—		1,558		20,549		22,107		4,794		2014	—	02/17/2015
Clarion Healthcare Facility	Clarion, PA	—		(a)	462		5,377		—		462		5,377		5,839		1,553		2012	—	06/01/2015
Webster Healthcare Facility	Webster, TX	—		(a)	1,858		20,140		—		1,858		20,140		21,998		4,511		2015	—	06/05/2015
Augusta Healthcare Facility	Augusta, ME	—		(a)	556		14,401		103		556		14,504		15,060		3,455		2010	—	07/22/2015
Cincinnati Healthcare Facility III	Cincinnati, OH	—		(a)	446		10,239		4		446		10,243		10,689		2,304		2014	—	07/22/2015
Florence Healthcare Facility	Florence, KY	—		(a)	650		9,919		—		650		9,919		10,569		2,223		2014	—	07/22/2015
Oakland Healthcare Facility	Oakland, ME	—		(a)	229		5,416		—		229		5,416		5,645		1,400		2004	—	07/22/2015
Wyomissing Healthcare Facility	Wyomissing, PA	—		(a)	1,504		20,193		—		1,504		20,193		21,697		4,615		2007	—	07/24/2015
Luling Healthcare Facility	Luling, TX	—		(a)	824		7,530		—		824		7,530		8,354		1,712		2003	—	07/30/2015
Omaha Healthcare Facility	Omaha, NE	—		(a)	1,259		9,796		—		1,259		9,796		11,055		2,113		2014	—	10/14/2015
Sherman Healthcare Facility	Sherman, TX	—		(a)	1,679		23,926		—		1,679		23,926		25,605		5,051		2005	2010	11/20/2015
Sherman Healthcare Facility II	Sherman, TX	—		(a)	214		3,209		—		214		3,209		3,423		683		2005	—	11/20/2015
Fort Worth Healthcare Facility III	Fort Worth, TX	—		(a)	3,120		9,312		—		3,120		9,312		12,432		1,970		1998	2007/2015	12/23/2015
Oklahoma City Healthcare Facility	Oklahoma City, OK	—		(a)	4,626		30,509		99		4,626		30,608		35,234		6,663		1985	1998/2003	12/29/2015
Oklahoma City Healthcare Facility II	Oklahoma City, OK	—		(a)	991		8,366		—		991		8,366		9,357		1,942		1994	1999	12/29/2015
Edmond Healthcare Facility	Edmond, OK	—		(a)	796		3,199		—		796		3,199		3,995		749		2002	—	01/20/2016
Oklahoma City Healthcare Facility III	Oklahoma City, OK	—		(a)	452		1,081		—		452		1,081		1,533		260		2006	—	01/27/2016
Oklahoma City Healthcare Facility IV	Oklahoma City, OK	—		(a)	368		2,344		28		368		2,372		2,740		549		2007	—	01/27/2016
Newcastle Healthcare Facility	Newcastle, OK	—		(a)	412		1,173		—		412		1,173		1,585		281		1995	1999	02/03/2016
Oklahoma City Healthcare Facility V	Oklahoma City, OK	—		(a)	541		12,445		—		541		12,445		12,986		2,891		2008	—	02/11/2016
Rancho Mirage Healthcare Facility	Rancho Mirage, CA	—		(a)	2,724		7,626		29,843		2,725		37,468		40,193		5,035		2018	—	03/01/2016
Oklahoma City Healthcare Facility VI	Oklahoma City, OK	—		(a)	896		3,684		84		896		3,768		4,664		873		2007	—	03/07/2016
Oklahoma City Healthcare Facility VII	Oklahoma City, OK	—		(a)	3,203		32,380		—		3,203		32,380		35,583		6,408		2016	—	06/22/2016
Las Vegas Healthcare Facility	Las Vegas, NV	—		(a)	2,614		639		22,091		2,895		22,449		25,344		3,577		2017	—	06/24/2016
Oklahoma City Healthcare Facility VIII	Oklahoma City, OK	—		(a)	2,002		15,384		—		2,002		15,384		17,386		3,003		1997	2008	06/30/2016
Marlton Healthcare Facility	Marlton, NJ	—		(a)	—		57,154		5		—		57,159		57,159		10,185		1995	—	11/01/2016
Grand Rapids Healthcare Facility	Grand Rapids, MI	—		(a)	2,533		39,487		1,554		2,533		41,041		43,574		8,282		2008	—	12/07/2016
Corpus Christi Healthcare Facility	Corpus Christi, TX	—		(a)	975		4,963		793		1,002		5,729		6,731		1,150		1992	2016	12/22/2016
Aurora Healthcare Facility	Aurora, IL	—		(a)	973		9,632		19		973		9,651		10,624		1,768		2002	—	03/30/2017
Allen Healthcare Facility	Allen, TX	—		(a)	857		20,582		—		857		20,582		21,439		3,763		2007	—	03/31/2017
Austin Healthcare Facility	Austin, TX	—		(a)	1,368		32,039		—		1,368		32,039		33,407		5,858		2012	—	03/31/2017


				Initial Cost		Cost Capitalized Subsequent to Acquisition (b)	Gross Amount Carried at December 31, 2023
Property Description	Location	Encumbrances		Land	Buildings and Improvements		Land	Buildings and Improvements (c)	Total	Accumulated Depreciation (d)	Year Constructed	Year Renovated	Date Acquired
Beaumont Healthcare Facility	Beaumont, TX	—	(a)	946	8,372	—	946	8,372	9,318	1,539	1991	—	03/31/2017
San Antonio Healthcare Facility	San Antonio, TX	—	(a)	1,813	11,706	—	1,813	11,706	13,519	2,076	1984	(e)	06/29/2017
Silverdale Healthcare Facility	Silverdale, WA	—	(a)	1,530	7,506	48	1,530	7,554	9,084	1,469	2005	—	08/25/2017
Silverdale Healthcare Facility II	Silverdale, WA	—	(a)	1,542	4,981	—	1,542	4,981	6,523	1,052	2007	—	09/20/2017
Saginaw Healthcare Facility	Saginaw, MI	—	(a)	1,251	15,878	235	1,251	16,113	17,364	3,519	2002	—	12/21/2017
Carrollton Healthcare Facility	Carrollton, TX	—	(a)	1,995	5,870	39	1,995	5,909	7,904	943	2015	—	04/27/2018
Katy Healthcare Facility	Katy, TX	—	(a)	1,443	12,114	—	1,443	12,114	13,557	1,742	2015	—	06/08/2018
Indianola Healthcare Facility	Indianola, IA	—	(a)	330	5,698	67	330	5,765	6,095	828	2014	—	09/26/2018
Indianola Healthcare Facility II	Indianola, IA	—	(a)	709	6,061	—	709	6,061	6,770	904	2011	—	09/26/2018
Benton Healthcare Facility	Benton, AR	—	(a)	—	19,048	—	—	19,048	19,048	2,694	1992/1999	2012	10/17/2018
Benton Healthcare Facility II	Benton, AR	—	(a)	—	1,647	—	—	1,647	1,647	259	1983	—	10/17/2018
Bryant Healthcare Facility	Bryant, AR	—	(a)	930	3,539	57	930	3,596	4,526	554	1995	—	10/17/2018
Hot Springs Healthcare Facility	Hot Springs, AR	—	(a)	384	2,077	—	384	2,077	2,461	334	2009	—	10/17/2018
Clive Healthcare Facility	Clive, IA	—	(a)	336	22,332	158	336	22,490	22,826	3,637	2008	—	11/26/2018
Valdosta Healthcare Facility	Valdosta, GA	—	(a)	659	5,626	—	659	5,626	6,285	907	2004	—	11/28/2018
Valdosta Healthcare Facility II	Valdosta, GA	—	(a)	471	2,780	—	471	2,780	3,251	455	1992	—	11/28/2018
Bryant Healthcare Facility II	Bryant, AR	—	(a)	647	3,364	—	647	3,364	4,011	419	2016	—	08/16/2019
Laredo Healthcare Facility	Laredo, TX	—	(a)	—	12,137	—	—	12,137	12,137	1,412	1998	2023	09/19/2019
Laredo Healthcare Facility II	Laredo, TX	—	(a)	—	23,677	83	—	23,760	23,760	2,816	1998	—	09/19/2019
Poplar Bluff Healthcare Facility	Poplar Bluff, MO	—	(a)	—	13,515	—	—	13,515	13,515	1,579	2013	—	09/19/2019
Tucson Healthcare Facility	Tucson, AZ	—	(a)	—	5,998	—	—	5,998	5,998	704	1998	—	09/19/2019
Akron Healthcare Facility	Green, OH	—	(a)	3,503	38,512	—	3,503	38,512	42,015	4,320	2012	—	10/04/2019
Akron Healthcare Facility II	Green, OH	—	(a)	1,085	10,277	—	1,085	10,277	11,362	1,385	2013	—	10/04/2019
Akron Healthcare Facility III	Akron, OH	—	(a)	2,206	26,044	—	2,206	26,044	28,250	2,823	2008	—	10/04/2019
Alexandria Healthcare Facility	Alexandria, LA	—	(a)	—	5,076	—	—	5,076	5,076	550	2007	—	10/04/2019
Appleton Healthcare Facility	Appleton, WI	—	(a)	414	1,900	—	414	1,900	2,314	274	2011	—	10/04/2019
Austin Healthcare Facility II	Austin, TX	—	(a)	3,229	7,534	(2,807)	2,195	5,761	7,956	641	2006	—	10/04/2019
Bellevue Healthcare Facility	Green Bay, WI	—	(a)	567	1,269	—	567	1,269	1,836	190	2010	—	10/04/2019
Bonita Springs Healthcare Facility	Bonita Springs, FL	—		1,199	4,373	—	1,199	4,373	5,572	487	2002	2005	10/04/2019
Bridgeton Healthcare Facility	Bridgeton, MO	—	(a)	—	39,740	—	—	39,740	39,740	4,289	2012	—	10/04/2019
Covington Healthcare Facility	Covington, LA	—	(a)	2,238	16,635	—	2,238	16,635	18,873	1,786	1984	—	10/04/2019
Crestview Healthcare Facility	Crestview, FL	—		400	1,536	—	400	1,536	1,936	191	2004	2010	10/04/2019
Dallas Healthcare Facility	Dallas, TX	—	(a)	6,072	27,457	—	6,072	27,457	33,529	2,900	2011	—	10/04/2019
De Pere Healthcare Facility	De Pere, WI	—	(a)	615	1,596	—	615	1,596	2,211	231	2005	—	10/04/2019
Denver Healthcare Facility	Thornton, CO	—	(a)	3,586	32,363	—	3,586	32,363	35,949	3,525	1962	2018	10/04/2019
El Segundo Healthcare Facility	El Segundo, CA	—		2,659	9,016	—	2,659	9,016	11,675	981	2009	—	10/04/2019
Fairlea Healthcare Facility	Fairlea, WV	—		139	1,910	—	139	1,910	2,049	220	1999	—	10/04/2019
Fayetteville Healthcare Facility	Fayetteville, AR	—	(a)	485	24,855	—	485	24,855	25,340	2,669	1994	2009	10/04/2019
Fort Myers Healthcare Facility	Fort Myers, FL	—		2,153	2,387	(562)	2,012	1,966	3,978	36	1999	—	10/04/2019
Fort Myers Healthcare Facility II	Fort Myers, FL	—		3,557	11,064	(2,304)	3,272	9,045	12,317	152	2010	2022	10/04/2019
Fort Walton Beach Healthcare Facility	Fort Walton Beach, FL	—		385	3,182	—	385	3,182	3,567	363	2005	—	10/04/2019


				Initial Cost		Cost Capitalized Subsequent to Acquisition (b)	Gross Amount Carried at December 31, 2023
Property Description	Location	Encumbrances		Land	Buildings and Improvements		Land	Buildings and Improvements (c)	Total	Accumulated Depreciation (d)	Year Constructed	Year Renovated	Date Acquired
Frankfort Healthcare Facility	Frankfort, KY	—		342	950	—	342	950	1,292	122	1993	2019	10/04/2019
Frisco Healthcare Facility	Frisco, TX	—	(a)	—	22,114	4,790	—	26,904	26,904	3,884	2010	2020	10/04/2019
Goshen Healthcare Facility	Goshen, IN	—	(a)	383	5,355	—	383	5,355	5,738	636	2010	—	10/04/2019
Hammond Healthcare Facility	Hammond, LA	—	(a)	2,693	23,750	—	2,693	23,750	26,443	2,648	2006	—	10/04/2019
Hammond Healthcare Facility II	Hammond, LA	—	(a)	950	12,147	—	950	12,147	13,097	1,339	2004	—	10/04/2019
Henderson Healthcare Facility	Henderson, NV	—		839	2,390	—	839	2,390	3,229	285	2000	—	10/04/2019
Houston Healthcare Facility III	Houston, TX	—	(a)	752	5,832	—	752	5,832	6,584	631	1998	2018	10/04/2019
Howard Healthcare Facility	Howard, WI	—	(a)	529	1,818	—	529	1,818	2,347	264	2011	—	10/04/2019
Jacksonville Healthcare Facility	Jacksonville, FL	—		1,233	6,173	—	1,233	6,173	7,406	708	2009	—	10/04/2019
Lafayette Healthcare Facility	Lafayette, LA	—	(a)	4,819	35,424	—	4,819	35,424	40,243	3,866	2004	2005	10/04/2019
Lakewood Ranch Healthcare Facility	Lakewood Ranch, FL	—		636	1,784	—	636	1,784	2,420	259	2008	—	10/04/2019
Las Vegas Healthcare Facility II	Las Vegas, NV	—		651	5,323	—	651	5,323	5,974	603	2007	—	10/04/2019
Lehigh Acres Healthcare Facility	Lehigh Acres, FL	—		441	2,956	—	441	2,956	3,397	351	2002	—	10/04/2019
Lubbock Healthcare Facility	Lubbock, TX	—	(a)	5,210	39,939	—	5,210	39,939	45,149	4,282	2003	—	10/04/2019
Manitowoc Healthcare Facility	Manitowoc, WI	—	(a)	257	1,733	—	257	1,733	1,990	242	2003	—	10/04/2019
Manitowoc Healthcare Facility II	Manitowoc, WI	—	(a)	250	11,231	—	250	11,231	11,481	1,328	1964	2010	10/04/2019
Marinette Healthcare Facility	Marinette, WI	—	(a)	208	1,002	—	208	1,002	1,210	144	2008	—	10/04/2019
New Bedford Healthcare Facility	New Bedford, MA	—		2,464	26,297	(27,522)	115	1,124	1,239	32	1942	1995	10/04/2019
New Braunfels Healthcare Facility	New Braunfels, TX	—	(a)	2,568	11,386	—	2,568	11,386	13,954	1,239	2007	—	10/04/2019
North Smithfield Healthcare Facility	North Smithfield, RI	—	(a)	1,309	14,024	—	1,309	14,024	15,333	1,611	1965	2000	10/04/2019
Oklahoma City Healthcare Facility IX	Oklahoma City, OK	—	(a)	1,316	9,822	—	1,316	9,822	11,138	1,220	2007	—	10/04/2019
Oshkosh Healthcare Facility	Oshkosh, WI	—	(a)	414	2,043	(1)	413	2,043	2,456	275	2010	—	10/04/2019
Palm Desert Healthcare Facility	Palm Desert, CA	—		582	5,927	—	582	5,927	6,509	718	2005	—	10/04/2019
Rancho Mirage Healthcare Facility II	Rancho Mirage, CA	—		2,286	5,481	(3,767)	1,227	2,773	4,000	—	2008	2022	10/04/2019
San Antonio Healthcare Facility III	San Antonio, TX	—	(a)	1,824	22,809	—	1,824	22,809	24,633	2,432	2012	—	10/04/2019
San Antonio Healthcare Facility IV	San Antonio, TX	—	(a)	—	31,694	—	—	31,694	31,694	3,379	1987	—	10/04/2019
San Antonio Healthcare Facility V	San Antonio, TX	—	(a)	3,273	19,697	1,023	3,273	20,720	23,993	2,469	2017	—	10/04/2019
Santa Rosa Beach Healthcare Facility	Santa Rosa Beach, FL	—		741	3,049	—	741	3,049	3,790	326	2003	—	10/04/2019
Savannah Healthcare Facility	Savannah, GA	—		2,300	20,186	—	2,300	20,186	22,486	2,168	2014	—	10/04/2019
Sturgeon Bay Healthcare Facility	Sturgeon Bay, WI	—	(a)	248	700	—	248	700	948	111	2007	—	10/04/2019
Victoria Healthcare Facility	Victoria, TX	—	(a)	328	12,908	—	328	12,908	13,236	1,414	2013	—	10/04/2019
Victoria Healthcare Facility II	Victoria, TX	—	(a)	446	12,986	—	446	12,986	13,432	1,409	1998	—	10/04/2019
Wilkes-Barre Healthcare Facility	Mountain Top, PA	—	(a)	821	4,139	—	821	4,139	4,960	509	2012	—	10/04/2019
Yucca Valley Healthcare Facility	Yucca Valley, CA	—		901	4,788	(4,310)	241	1,138	1,379	19	2009	—	10/04/2019
Tucson Healthcare Facility II	Tucson, AZ	—	(a)	—	—	25,324	—	25,324	25,324	1,735	2021	—	12/26/2019
Tucson Healthcare Facility III	Tucson, AZ	—	(a)	1,763	—	8,177	1,763	8,177	9,940	983	2020	—	12/27/2019
Grimes Healthcare Facility	Grimes, IA	—	(a)	831	3,690	—	831	3,690	4,521	417	2018	—	02/19/2020
Tampa Healthcare Facility	Tampa, FL	—	(a)	—	10,297	—	—	10,297	10,297	1,140	2015	—	09/08/2020
Tucson Healthcare Facility IV	Tucson, AZ	—		—	58	18,057	—	18,115	18,115	1,289	2022	—	12/22/2020
Greenwood Healthcare Facility	Greenwood, IN	—	(a)	1,603	22,588	—	1,603	22,588	24,191	1,591	2008	2018	04/19/2021
Clive Healthcare Facility II	Clive, IA	—	(a)	1,555	17,898	—	1,555	17,898	19,453	1,073	2008	—	12/08/2021


					Initial Cost				Cost Capitalized Subsequent to Acquisition (b)		Gross Amount Carried at December 31, 2023
Property Description	Location	Encumbrances			Land		Buildings and Improvements				Land		Buildings and Improvements (c)		Total		Accumulated Depreciation (d)		Year Constructed	Year Renovated	Date Acquired
Clive Healthcare Facility III	Clive, IA	—		(a)	843		12,299		57		843		12,356		13,199		634		2008	—	12/08/2021
Clive Healthcare Facility IV	Clive, IA	—		(a)	720		7,863		—		720		7,863		8,583		499		2009	2018	12/08/2021
Clive Undeveloped Land	Clive, IA	—			1,061		—		—		1,061		—		1,061		—		—	—	12/08/2021
Clive Undeveloped Land II	Clive, IA	—			460		—		—		460		—		460		—		—	—	12/08/2021
Yukon Healthcare Facility	Yukon, OK	—			1,288		16,779		—		1,288		16,779		18,067		835		2020	—	03/10/2022
Pleasant Hills Healthcare Facility	Pleasant Hills, PA	—			922		12,905		—		922		12,905		13,827		701		2015	—	05/12/2022
Prosser Healthcare Facility I	Prosser, WA	—			282		1,933		—		282		1,933		2,215		105		2020	—	05/20/2022
Prosser Healthcare Facility II	Prosser, WA	—			95		3,374		—		95		3,374		3,469		176		2013	2019	05/20/2022
Prosser Healthcare Facility III	Prosser, WA	—			59		2,070		—		59		2,070		2,129		107		2013	—	05/20/2022
Tampa Healthcare Facility II	Tampa, FL	—			—		47,042		—		—		47,042		47,042		1,821		2022	—	07/20/2022
Escondido Healthcare Facility	Escondido, CA	—			—		57,675		—		—		57,675		57,675		2,163		2021	—	07/21/2022
West Palm Beach Healthcare Facility	West Palm Beach, FL	—			2,064		7,011		30		2,065		7,040		9,105		107		1999	2007/2019	06/15/2023
Burr Ridge Healthcare Facility	Burr Ridge, IL	—			4,828		46,152		—		4,828		46,152		50,980		387		2010	—	09/27/2023
		$	—		$	165,071	$	1,631,875	$	58,862	$	157,821	$	1,697,987	$	1,855,808	$	227,156

(a)Property is contributed to the pool of unencumbered properties of the Company's credit facility. As of December 31, 2023, 111 commercial real estate properties were contributed to the pool of unencumbered properties under the Company's credit facility and the Company had an outstanding principal balance of $525,000,000.

(b)The reduction to costs capitalized subsequent to acquisition primarily include impairment charges, property dispositions and other adjustments.

(c)The aggregated cost for federal income tax purposes is approximately $2,011,524,000 (unaudited).

(d)The Company’s assets are depreciated or amortized using the straight-line method over the useful lives of the assets by class. Generally, buildings and improvements are depreciated over 15-40 years and tenant improvements are depreciated over the shorter of lease term or expected useful life.

(e)Property is currently under renovation.

NOTES TO SCHEDULE III — REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION

December 31, 2023

(in thousands)


	Year Ended December 31,
	2023		2022		2021
Real Estate:
Balance at beginning of year	$	2,089,200	$	2,015,330	$	2,890,958
Additions:
Acquisitions	60,055		144,424		66,890
Improvements	1,727		4,735		23,288
Other adjustments	—		182		978
Deductions:
Impairment	(28,651)		(53,230)		(29,673)
Dispositions	(266,523)		(22,241)		(936,594)
Other adjustments	—		—		(517)
Balance at end of year	$	1,855,808	$	2,089,200	$	2,015,330

Accumulated Depreciation:
Balance at beginning of year	$	(209,118)	$	(165,784)	$	(197,134)
Additions:
Depreciation	(52,404)		(51,584)		(56,999)
Deductions:
Impairment	8,409		8,250		2,507
Dispositions	25,957		—		85,325
Other adjustments	—		—		517
Balance at end of year	$	(227,156)	$	(209,118)	$	(165,784)

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net Income (Loss)	$ 24,042	$ (7,978)	$ 402,660

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of the Company, the Operating Partnership, and their wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements and accompanying notes in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

Cash consists of demand deposits at commercial banks. Cash equivalents consist of highly liquid investments in money market funds with original maturities of three months or less at the time of purchase. Restricted cash consists of cash held in an escrow account in accordance with a tenant's lease agreement. Restricted cash is reported in other assets in the accompanying consolidated balance sheets. The Company maintains its cash, cash equivalents and restricted cash at various financial institutions. As of December 31, 2023, certain of the Company’s cash deposits exceeded federally insured amounts. To date, the Company has experienced no loss or lack of access to cash in its accounts. The Company attempts to limit cash investments to financial institutions with high credit standing; therefore, the Company believes it is not exposed to any significant credit risk on its cash deposits.

Investment in Real Estate

Real estate costs related to the acquisition, development, construction and improvement of properties are capitalized. Repair and maintenance costs are expensed as incurred, and significant replacements and improvements are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate assets. The Company considers the period of future benefit of an asset in determining the appropriate useful life. Real estate assets, other than land, are depreciated on a straight-line basis over each asset’s useful life. The Company anticipates the estimated useful lives of its assets by class as follows:


Buildings and improvements						15 – 40 years
Tenant improvements						Shorter of lease term or expected useful life
Furniture, fixtures, and equipment						3 – 10 years

Allocation of Purchase Price of Real Estate

Upon the acquisition of real estate properties, the Company evaluates whether the acquisition is a business combination or an asset acquisition. For both business combinations and asset acquisitions, the Company allocates the purchase price of properties to acquired tangible assets, consisting of land, buildings and improvements, and intangible assets and liabilities, consisting of the value of above-market and below-market leases and the value of in-place leases. For asset acquisitions, the Company capitalizes transaction costs and allocates the purchase price using a relative fair value method allocating all accumulated costs. For business combinations, the Company expenses transaction costs incurred and allocates the purchase price based on the estimated fair value of each separately identifiable asset and liability. For the year ended December 31, 2023, all of the Company's acquisitions were determined to be asset acquisitions.

The fair value of the tangible assets of an acquired property (which includes land, buildings and improvements) is determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land and buildings and improvements based on management’s determination of the relative fair value of these assets.

The amount allocated to in-place leases includes an estimate of direct costs associated with obtaining a new tenant and opportunity costs associated with lost rentals that are avoided by acquiring an in-place lease. These lease intangibles are amortized to depreciation and amortization expense over the remaining terms of the respective leases. If a lease is terminated prior to its stated expiration, all unamortized amounts of in-place lease assets relating to that lease would be expensed.

The amounts allocated to above-market and below-market leases are recorded based on the present value of the difference between: (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) an estimate of current market lease rates for the corresponding leases, measured over a period equal to the remaining non-cancelable term of the lease including any fixed rate bargain renewal periods, with respect to a below-market lease. These above-market and below-market amounts are amortized as an adjustment of rental revenue over the remaining terms of the respective leases. If a lease is terminated prior to its stated expiration, all unamortized amounts of above-market and below-market lease values related to that lease would be recorded as an adjustment to rental revenue.

Held for Sale

The Company classifies a real estate property as held for sale upon satisfaction of all of the following criteria: (i) management commits to a plan to sell the property; (ii) the property is available for immediate sale in its present condition, subject only to terms that are usual and customary for sales of such properties; (iii) there is an active program to locate a buyer; (iv) the sale of the property is probable and transfer of the asset is expected to be completed within one year; (v) the property is being actively marketed for sale; and (vi) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.

Upon the determination to classify a property as held for sale, the Company ceases depreciation and amortization on the real estate property held for sale, as well as the amortization of any related intangible assets. Such properties are recorded at the lesser of the carrying value or estimated fair value less estimated costs to sell.

Impairments

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate assets may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate assets may not be recoverable, the Company assesses the recoverability of the asset group by estimating undiscounted future cash flows, including eventual disposition. Based on this analysis, if the Company does not believe that it will be able to recover the carrying value of the asset group, an impairment charge will be recorded to the extent that the carrying value exceeds the estimated fair value of the asset group.

When developing estimates of expected future cash flows, the Company makes certain assumptions regarding future market rental rates subsequent to the expiration of current lease arrangements, property operating expenses, terminal capitalization and discount rates, probability weighting of potential uses of the property, sale prices of comparable properties, required tenant improvements and the number of years the property will be held for investment. The use of alternative assumptions in the future cash flow analysis could result in a different determination of the property’s future cash flows and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate assets.

In addition, the Company determines fair value by using a direct capitalization method, a discounted cash flow method using the assumptions noted above, or by utilizing comparable market information based on the view of a market participant. The use of alternative assumptions in these approaches could result in a different determination of the property’s estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate assets.

The Company accounts for goodwill in accordance with Accounting Standards Codification, or ASC, 350, Intangibles - Goodwill and Other, and allocates its goodwill to its reporting units, which have been determined to be at the individual property level. Goodwill has an indefinite life and is not amortized.

The Company evaluates goodwill for impairment at least annually, as of the last day of each year, or upon the occurrence of a triggering event. A triggering event is an event or circumstance that would more-likely-than-not indicate that the fair value of a reporting unit is below its carrying value.

The Company has the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. Under a qualitative assessment, the impairment analysis for goodwill represents an evaluation of whether it is more-likely-than-not the reporting unit's fair value is less than its carrying value, including goodwill. If a qualitative analysis indicates that it is more-likely-than-not that the estimated carrying value of a reporting unit, including goodwill, exceeds its fair value, the Company performs the quantitative analysis. The quantitative analysis consists of estimating the fair value of each reporting unit using discounted projected future cash flows and comparing those estimated fair values with the carrying values, which include the allocated goodwill. If the estimated fair value is less than the carrying value, the Company would then recognize a goodwill impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to that reporting unit.

Deferred Financing Costs

Deferred financing costs are loan fees, legal fees and other third-party costs associated with obtaining and further modifying financing. These costs are amortized over the terms of the respective financing agreements using the effective interest method. Deferred financing costs related to the term loan portion of the credit facility are recorded as a reduction of the related debt on the accompanying consolidated balance sheets. Deferred financing costs related to the revolving line of credit are recorded in other assets in the accompanying consolidated balance sheets.

Fair Value

ASC 820, Fair Value Measurements and Disclosures, or ASC 820, defines fair value, establishes a framework for measuring fair value in accordance with GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is intended to be a market-based measurement, as opposed to a transaction-specific measurement.

Fair value is defined by ASC 820 as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate the fair value. Assets and liabilities are measured using inputs from three levels of the fair value hierarchy, as follows:

Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market is defined as a market in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2—Inputs other than quoted prices for similar assets and liabilities in active markets that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs).

Level 3—Unobservable inputs, only used to the extent that observable inputs are not available, reflect the Company’s assumptions about the pricing of an asset or liability.

Revenue Recognition and Tenant Receivables

The majority of the Company's revenue is derived from rental revenue, which is accounted for in accordance with ASC 842, Leases, or ASC 842. Under ASC 842, rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). For lease arrangements where it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. Differences between rental revenue recognized and amounts contractually due under the lease agreements are credited or charged to straight-line rent receivable. Tenant reimbursements, which are comprised of additional amounts recoverable from tenants for common area maintenance expenses and certain other recoverable expenses, are recognized when the services are provided and the performance obligations are satisfied.

Share Repurchase Program

The Company’s Amended and Restated Share Repurchase Program, or the SRP, allows for repurchases of shares of the Company’s common stock upon meeting certain criteria. The SRP provides that all repurchases during any calendar year, including those redeemable upon death or a "Qualifying Disability" (as defined in the Company's SRP) of a stockholder, be limited to those that can be funded with equivalent proceeds raised from the Company's distribution reinvestment plan, or DRIP, during the prior calendar year and other operating funds, if any, as the Company's board of directors, or the Board, in its sole discretion, may reserve for this purpose.

Repurchases of shares of the Company’s common stock are at the sole discretion of the Board, provided, however, that the Company limits the number of shares repurchased during any calendar year to 5.0% of the total number of shares of common stock outstanding as of December 31st of the previous calendar year. The SRP is subject to terms and limitations, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation and DRIP funding limitations and any amendments to the plan. In addition, the Board, in its sole discretion, may suspend (in whole or in part) the SRP at any time, and may amend, reduce, terminate or otherwise change the SRP upon 30 days' prior notice to the Company’s stockholders for any reason it deems appropriate.

The Company will currently only repurchase shares due to death and involuntary exigent circumstances in accordance with the SRP, subject in each case to the terms and limitations of the SRP. Under the SRP, the Company may waive certain of the terms and requirements of the SRP in the event of the death of a stockholder who is a natural person, including shares held through an Individual Retirement Account or other retirement or profit-sharing plan, and certain trusts meeting the requirements of the SRP. The Company may also waive certain of the terms and requirements of the SRP in the event of an involuntary exigent circumstance, as determined by the Company or any of the executive officers thereof, in its or their sole discretion.

Distribution Policy

In order to maintain its status as a REIT, the Company is required to make distributions each taxable year equal to at least 90% of its REIT taxable income, computed without regard to the dividends paid deduction and excluding capital gains. To the extent funds are available, the Company intends to continue to pay regular distributions to stockholders. Distributions are paid to stockholders of record as of the applicable record dates. Distributions to stockholders are determined by the Board and are dependent upon a number of factors, including funds available for the payment of distributions, financial condition, the timing

of property acquisitions, capital expenditure requirements, and annual distribution requirements in order to maintain the Company’s status as a REIT.

Stock-based Compensation

On March 6, 2020, the Board approved the Amended and Restated 2014 Restricted Share Plan, or the A&R Incentive Plan, pursuant to which the Company has the authority and power to grant awards of restricted shares of its Class A common stock to its directors, officers and employees. The Company accounts for its stock awards in accordance with ASC 718-10, Compensation—Stock Compensation. ASC 718-10 requires that compensation cost for all stock awards be calculated and amortized over the service period (generally equal to the vesting period). For performance-based awards, compensation costs are recognized over the service period if it is probable that the performance condition will be satisfied, with changes of the assessment at each reporting period and recording the effect of the change in the compensation cost as a cumulative catch-up adjustment. The compensation costs for restricted stock are recognized based on the fair value of the restricted stock awards at grant date. Forfeitures are accounted for as they occur.

Earnings Per Share

The Company calculates basic earnings per share by dividing net income (loss) attributable to common stockholders for the period by the weighted average shares of its common stock outstanding for that period. All classes of common stock are allocated net income (loss) attributable to common stockholders at the same rate per share and receive the same gross distribution per share. Diluted earnings per share is computed based on the weighted average number of shares outstanding and all potentially dilutive securities. Shares of non-vested restricted common stock and performance-based deferred stock unit awards, or Performance DSUs, are considered to be participating securities because they contain non-forfeitable rights to distributions and give rise to potentially dilutive shares of common stock.

Reportable Segments

ASC 280, Segment Reporting, establishes standards for reporting financial and descriptive information about an entity’s reportable segments. As of December 31, 2023 and December 31, 2022, all of the Company's consolidated revenues were generated from real estate investments in healthcare properties. The Company’s chief operating decision maker evaluates operating performance of healthcare properties on an individual property level, which are aggregated into one operating segment due to their similar economic characteristics. The aggregated operating segment is the Company's only reportable segment.

Derivative Instruments and Hedging Activities

As required by ASC 815, Derivatives and Hedging, or ASC 815, the Company records all derivative instruments at fair value as assets and liabilities on its consolidated balance sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.

In accordance with the fair value measurement guidance in Accounting Standards Update, or ASU, 2011-04, Fair Value Measurement, the Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

The Company is exposed to variability in expected future cash flows that are attributable to interest rate changes in the normal course of business. The Company’s primary strategy in entering into derivative contracts is to add stability to future cash flows by managing its exposure to interest rate fluctuations. The Company utilizes derivative instruments, including interest rate swaps, to effectively convert its variable rate debt to fixed rate debt. The Company does not enter into derivative instruments for speculative purposes.

In accordance with ASC 815, the Company designates interest rate swap contracts as cash flow hedges of floating-rate borrowings. For derivative instruments that are designated and qualify as cash flow hedges, the gains or losses on the derivative instruments are reported as other comprehensive (loss) income - unrealized (loss) gain on interest rate swaps, net in the consolidated statements of comprehensive income and are reclassified into earnings in the same line item associated with the forecasted transaction in the same period during which the hedged transactions affect earnings.

Income Taxes

The Company currently qualifies and is taxed as a REIT under Sections 856 through 860 of the Code. Accordingly, it will generally not be subject to corporate U.S. federal or state income tax to the extent that it makes qualifying distributions to stockholders, and provided it satisfies, on a continuing basis, through actual investment and operating results, the REIT requirements, including certain asset, income, distribution and stock ownership tests. If the Company fails to qualify as a REIT,

it would be subject to U.S. federal, state and local income taxes and may be precluded from qualifying as a REIT for the subsequent four taxable years following the year in which it lost its REIT qualification, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Accordingly, failure to qualify as a REIT could have a material adverse impact on the results of operations and amounts available for distribution to stockholders.

The dividends paid deduction of a REIT for qualifying dividends paid to its stockholders is computed using the Company’s taxable income as opposed to net income reported in the consolidated financial statements. Taxable income, generally, will differ from net income reported in the consolidated financial statements because the determination of taxable income is based on tax provisions and not financial accounting principles.

The Company has concluded that there was no impact related to uncertain tax positions from results of operations of the Company for the years ended December 31, 2023, 2022 and 2021. The earliest tax year currently subject to examination is 2020.

Recently Issued Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods for fiscal years beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is evaluating the disclosure requirements of ASU 2023-07 and does not anticipate that this update will have a material impact on its consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table presents a reconciliation of the beginning of year and end of year cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the totals shown in the consolidated statements of cash flows (amounts in thousands):


	Year Ended December 31,
	2023		2022		2021
Beginning of year:
Cash and cash equivalents	$	12,917	$	32,359	$	53,174
Restricted cash	166		521		14,735
Cash, cash equivalents and restricted cash	$	13,083	$	32,880	$	67,909

End of year:
Cash and cash equivalents	$	202,019	$	12,917	$	32,359
Restricted cash	166		166		521
Cash, cash equivalents and restricted cash	$	202,185	$	13,083	$	32,880

Schedule of Estimated Useful Lives of Assets by Class

The Company anticipates the estimated useful lives of its assets by class as follows:


Buildings and improvements						15 – 40 years
Tenant improvements						Shorter of lease term or expected useful life
Furniture, fixtures, and equipment						3 – 10 years

Real Estate (Tables)

12 Months Ended

Dec. 31, 2023

Real Estate [Abstract]

Schedule of Consideration Transferred for Properties Acquired

The following table summarizes the consideration transferred and the purchase price allocation for acquisitions during the year ended December 31, 2023 (amounts in thousands):


Property Description	Date Acquired	Ownership Percentage	Consideration Transferred (amount in thousands)
West Palm Beach Healthcare Facility	06/15/2023	100%	$	9,920
Burr Ridge Healthcare Facility	09/27/2023	100%	59,902



Total			$	69,822

Schedule of Allocation of Acquisitions


	Total
Land	$	6,892
Building and improvements	51,337
Tenant improvements	1,826
In-place leases	9,767

Total assets acquired	$	69,822

Schedule of Goodwill

The following table summarizes the rollforward of goodwill for the years ended December 31, 2023 and 2022 (amounts in thousands):


	Year Ended December 31,
	2023		2022
Balance at beginning of year	$	21,710	$	23,284
Impairment losses	(4,010)		(1,574)
Balance at end of year	$	17,700	$	21,710

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Major Classes of Assets and Liabilities Classified as Held for Sale and Operations Reflected in Discontinued Operations

The operations reflected in income from discontinued operations (which consisted solely of the Company's former data center segment) on the consolidated statements of comprehensive income for the year ended December 31, 2021, were as follows (amounts in thousands):


	Year Ended December 31,
		2021
Revenue:
Rental revenue		$	57,903
Lease termination revenue		7,075
Total revenue		64,978
Expenses:
Rental expenses		15,737



Depreciation and amortization		11,759


Total expenses		27,496
Interest and other expense, net (1)		31,839
Income from discontinued operations		5,643
Gain on real estate dispositions		395,801
Net income from discontinued operations attributable to common stockholders		$	401,444

(1) Interest expense attributable to discontinued operations for the year ended December 31, 2021 was $31,856,000, which related to notes payable on certain data center properties. On July 22, 2021, in connection with the Data Center Sale, the Company paid off all data center and healthcare related notes payable, with an outstanding principal balance of $450,806,000 at the time of repayment and incurred approximately $23,738,000 of debt extinguishment costs related to the data center properties.

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-3

+ Details

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2023

Finite-Lived Intangible Assets, Net [Abstract]

Schedule of Intangible Assets, Net

Intangible assets, net, consisted of the following as of December 31, 2023 and 2022 (amounts in thousands, except weighted average remaining life amounts):


	December 31, 2023		December 31, 2022
In-place leases, net of accumulated amortization of $95,325 and $83,788, respectively (with a weighted average remaining life of 7.8 years and 8.9 years, respectively)	$	125,188	$	155,365
Above-market leases, net of accumulated amortization of $7,131 and $6,451, respectively (with a weighted average remaining life of 6.7 years and 7.9 years, respectively)	9,811		12,118
	$	134,999	$	167,483

Schedule of Estimated Future Amortization of Intangible Assets

Estimated amortization expense on the intangible assets as of December 31, 2023, for each of the next five years ending December 31 and thereafter, is as follows (amounts in thousands):


Year	Amount
2024	$	20,351
2025	18,362
2026	16,815
2027	15,238
2028	13,704
Thereafter	50,529
	$	134,999

Intangible Liabilities, Net (Tables)

12 Months Ended

Dec. 31, 2023

Intangible Lease Liabilities, Net [Abstract]

Schedule of Intangible Liabilities, Net

Intangible liabilities, net, consisted of the following as of December 31, 2023 and 2022 (amounts in thousands, except weighted average remaining life amounts):


	December 31, 2023		December 31, 2022
Below-market leases, net of accumulated amortization of $7,417 and $5,923, respectively (with a weighted average remaining life of 7.4 years and 8.4 years, respectively)	$	10,452	$	11,946

Schedule of Estimated Future Amortization of Intangible Liabilities

Estimated amortization of the intangible liabilities as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


Year	Amount
2024	$	1,494
2025	1,494
2026	1,475
2027	1,450
2028	1,146
Thereafter	3,393
	$	10,452

Leases (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Schedule of Future Minimum Rent to Lessor from Operating Leases

Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31, and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	177,637
2025	173,816
2026	168,143
2027	165,189
2028	160,868
Thereafter	829,692
Total	$	1,675,345

Schedule of Future Minimum Rent from Lessee for Operating Leases

The future rent payments, discounted by the Company's IBRs, under non-cancellable operating leases in effect as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


	December 31, 2023
2024	$	2,746
2025	2,768
2026	2,715
2027	2,681
2028	2,692
Thereafter	104,764
Total undiscounted rental payments	118,366
Less imputed interest	(77,208)
Total lease liabilities	$	41,158
Weighted average IBR	5.5		%
Weighted average remaining lease term	36.5 years

Schedule of Lease Cost

The following table provides details of the Company's total lease costs for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


		Year Ended December 31,
	Location in Consolidated Statements of Comprehensive Income		2023		2022		2021
Operating lease costs:
Ground lease costs (1)	Rental expenses		$	2,727	$	2,246	$	1,846
Ground lease costs (2)	Income from discontinued operations		—		—		414
Corporate operating lease costs	General and administrative expenses		735		741		1,129
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases			$	732	$	531	$	1,067

(1)The Company receives reimbursements from tenants for certain operating ground leases, which are recorded as rental revenue in the accompanying consolidated statements of comprehensive income.

(2)Amount relates to lease costs attributable to operating ground leases related to data center properties disposed of in the Data Center Sale on July 22, 2021.

Other Assets (Tables)

12 Months Ended

Dec. 31, 2023

Other Assets [Abstract]

Schedule of Other Assets

Other assets consisted of the following as of December 31, 2023 and 2022 (amounts in thousands):


	December 31, 2023		December 31, 2022
Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $1,917 and $889, respectively	$	2,271	$	3,178
Leasing commissions, net of accumulated amortization of $191 and $167, respectively	593		775

Restricted cash	166		166
Tenant receivables	2,398		1,736
Straight-line rent receivable	53,248		62,457

Prepaid and other assets	4,089		3,865
Derivative assets	17,060		27,990
	$	79,825	$	100,167

Accounts Payable and Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Other Liabilities

Accounts payable and other liabilities consisted of the following as of December 31, 2023 and 2022 (amounts in thousands):


	December 31, 2023		December 31, 2022
Accounts payable and accrued expenses	$	3,906	$	5,387
Accrued interest expense	1,714		1,941
Accrued property taxes	3,687		2,421
Accrued personnel costs	4,425		3,940

Distributions payable to stockholders	7,782		7,719
Performance DSUs distributions payable	1,140		573
Tenant deposits	877		877
Deferred rental income	6,393		7,761
Derivative liabilities	457		—

	$	30,381	$	30,619

Credit Facility (Tables)

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Schedule of Credit Facility

The Company's outstanding credit facility as of December 31, 2023 and 2022 consisted of the following (amounts in thousands):


	Weighted Average Contractual Rate(1)	December 31, 2023		December 31, 2022

Variable rate revolving line of credit	—%	$	—	$	8,000
Variable rate term loans fixed through interest rate swaps	3.28%	525,000		485,000
Variable rate term loans	—%	—		90,000
Total credit facility, principal amount outstanding	3.28%	525,000		583,000
Unamortized deferred financing costs related to credit facility term loans		(1,847)		(2,412)
Total credit facility, net of deferred financing costs		$	523,153	$	580,588

(1)Weighted average contractual rate is as of December 31, 2023.

Schedule of Future Principal Payments Due on Debt

The principal payments due on the credit facility as of December 31, 2023, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands):


	Amount
2024 (1)	$	250,000
2025	—
2026	—
2027	—
2028	275,000
Thereafter	—
	$	525,000

(1)The 2024 term loan has a maturity date of December 31, 2024, and, at the Company's election, may be extended for a period of six-months on no more than two occasions, subject to the satisfaction of certain conditions, including the payment of an extension fee. The Company currently meets these conditions and therefore may choose to exercise its option to extend the maturity date of the 2024 term loan.

Fair Value (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables show the fair value of the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (amounts in thousands):


	December 31, 2023
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets:
Derivative assets	$	—	$	17,060	$	—	$	17,060
Total assets at fair value	$	—	$	17,060	$	—	$	17,060
Liabilities:
Derivative liabilities	$	—	$	457	$	—	$	457
Total liabilities at fair value	$	—	$	457	$	—	$	457


	December 31, 2022
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets:
Derivative assets	$	—	$	27,990	$	—	$	27,990
Total assets at fair value	$	—	$	27,990	$	—	$	27,990

Schedule of Fair Value, Real Estate Assets Measured on Non-Recurring Basis

The following table shows the fair value of the Company's real estate assets, including intangible assets (at fair value measured on a non-recurring basis on the date of impairment), which the Company continues to own, as of December 31, 2023 (amounts in thousands):


	December 31, 2023
	Fair Value Hierarchy
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2) (1)		Significant Unobservable Inputs (Level 3)		Total Fair Value		Total Losses (2)
Real estate assets	$	—	$	21,400	$	16,200	$	37,600	$	20,758

(1)Amount includes $1,400,000 attributable to a real estate asset that was adjusted to fair value on December 31, 2022, which the Company continues to own as of December 31, 2023. The Company recorded total losses of $29,010,000 for this real estate asset during the year ended December 31, 2022.

(2)Amount represents losses recorded during 2023 and includes impairments of in-place lease intangible assets of $1,130,000, and real estate assets of $19,628,000 (including goodwill impairments of $792,000).

Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets

The following table sets forth quantitative information about the significant unobservable inputs of the Company’s Level 3 real estate recorded as of December 31, 2023:


Significant Unobservable Inputs	December 31, 2023
Overall capitalization rate	8.5%
Market rent per square foot	$45.00
Range of comparable sale price per square foot	$	60.86	-	$	98.04

Derivative Instruments and Hedging Activities (Tables)

12 Months Ended

Dec. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of the Notional Amount and Fair Value of Derivative Instruments

The following table summarizes the notional amount and fair value of the Company’s derivative instruments (amounts in thousands):


Derivatives Designated as Hedging Instruments	Balance Sheet Location	Effective Dates	Maturity Dates	December 31, 2023						December 31, 2022
				Outstanding Notional Amount		Fair Value of				Outstanding Notional Amount		Fair Value of
						Assets		(Liabilities)				Assets

Interest rate swaps	(1)	05/01/2022 to 05/01/2023	12/31/2024 to 01/31/2028	$	525,000	$	17,060	$	(457)	$	485,000	$	27,990

(1) Derivative assets and liabilities are reported in the consolidated balance sheets as other assets and accounts payable and other liabilities, respectively.

Schedule of Income and Losses Recognized on Derivative Instruments

The table below summarizes the amount of income and loss recognized on the interest rate derivatives designated as cash flow hedges for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


Derivatives in Cash Flow Hedging Relationships	Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives		Location of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)	Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)		Total Amount of Line Item in Consolidated Statements of Comprehensive Income







Year Ended December 31, 2023
Interest rate swaps	$	5,293	Interest expense	$	16,680	$	23,110


Year Ended December 31, 2022
Interest rate swaps	$	32,317	Interest expense	$	(520)	$	24,077


Year Ended December 31, 2021
Interest rate swaps - continuing operations	$	5,956	Interest expense	$	(8,031)	$	37,625
Interest rate swaps - discontinued operations	(37)		Income from discontinued operations	(1,647)		401,444
Total	$	5,919		$	(9,678)

Schedule of Offsetting of Derivative Assets

The following tables present the effect on the Company’s financial position had the Company made the election to offset its derivative positions as of December 31, 2023 and December 31, 2022 (amounts in thousands):


Offsetting of Derivative Assets
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Assets		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets Presented in the Balance Sheet		Financial Instruments Collateral		Cash Collateral		Net Amount
December 31, 2023	$	17,060	$	—	$	17,060	$	(457)	$	—	$	16,603
December 31, 2022	$	27,990	$	—	$	27,990	$	—	$	—	$	27,990

Schedule of Offsetting of Derivative Liabilities


Offsetting of Derivative Liabilities
							Gross Amounts Not Offset in the Balance Sheet
	Gross Amounts of Recognized Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Liabilities Presented in the Balance Sheet		Financial Instruments Collateral		Cash Collateral		Net Amount
December 31, 2023	$	457	$	—	$	457	$	(457)	$	—	$	—

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2023

Stockholders' Equity Note [Abstract]

Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)

The following table presents a rollforward of amounts recognized in accumulated other comprehensive income by component for the years ended December 31, 2023, 2022, and 2021 (amounts in thousands):


	Unrealized Income (Loss) on Derivative Instruments
Balance as of December 31, 2020	$	(20,444)
Other comprehensive income before reclassification	5,919
Amount of loss reclassified from accumulated other comprehensive loss to net income	9,678
Other comprehensive income	15,597
Balance as of December 31, 2021	$	(4,847)
Other comprehensive income before reclassification	32,317
Amount of loss reclassified from accumulated other comprehensive loss to net loss	520
Other comprehensive income	32,837
Balance as of December 31, 2022	$	27,990
Other comprehensive income before reclassification	5,293
Amount of income reclassified from accumulated other comprehensive income to net income	(16,680)
Other comprehensive loss	(11,387)
Balance as of December 31, 2023	$	16,603

Schedule of Reclassifications Out of Accumulated Other Comprehensive Income (Loss)

The following table presents reclassifications out of accumulated other comprehensive income for the years ended December 31, 2023, 2022 and 2021 (amounts in thousands):


Details about Accumulated Other Comprehensive Income Components	(Income) Loss Amounts Reclassified from Accumulated Other Comprehensive Income to Net Income (Loss)						Affected Line Items in the Consolidated Statements of Comprehensive Income
	Year Ended December 31,
	2023		2022		2021
Interest rate swap contracts - continuing operations	$	(16,680)	$	520	$	8,031	Interest expense
Interest rate swap contracts - discontinued operations	—		—		1,647		Income from discontinued operations
Interest rate swap contracts	$	(16,680)	$	520	$	9,678

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Nonvested Shares of Restricted Common Stock Activity

The following table summarizes restricted Class A common stock activity, including Performance DSUs, for the year ended December 31, 2023:


						Shares
Nonvested at December 31, 2022						1,423,690
Granted						793,718
Vested						(160,453)
Forfeited						(38,451)
Nonvested at December 31, 2023						2,018,504

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Characterization of Distributions Paid to Stockholders

The following table shows the character of distributions the Company paid on a percentage basis during the years ended December 31, 2023, 2022 and 2021:


	Year Ended December 31,
Character of Distributions (1):	2023		2022		2021
Ordinary dividends	61.41	%	40.94	%	27.91	%
Capital gain distributions	—	%	—	%	—	%
Nontaxable distributions	38.59	%	59.06	%	72.09	%
Total	100.00	%	100.00	%	100.00	%

	Year Ended December 31,
Character of Special Distribution (1):	2023		2022		2021
Ordinary dividends	—	%	—	%	12.39	%
Capital gain distributions	—	%	—	%	86.66	%
Nontaxable distributions	—	%	—	%	0.95	%
Total	—	%	—	%	100.00	%

(1)Attributable to Class A shares, Class I shares, Class T shares of common stock for the year ended December 31, 2023. Attributable to Class A shares, Class I shares, Class T shares, and Class T2 shares of common stock for the years ended December 31, 2022 and 2021.

Subsequent Events (Tables)

12 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

Schedule of Subsequent Events

The following table summarizes the Company's distributions paid to stockholders on January 8, 2024, for the period from December 1, 2023 through December 31, 2023 (amounts in thousands):


Payment Date	Common Stock	Cash		DRIP		Total Distribution
January 8, 2024	Class A	$	4,597	$	1,190	$	5,787
January 8, 2024	Class I	347		229		576
January 8, 2024	Class T	785		634		1,419

		$	5,729	$	2,053	$	7,782

The following table summarizes the Company's distributions paid to stockholders on February 7, 2024, for the period from January 1, 2024 through January 31, 2024 (amounts in thousands):


Payment Date	Common Stock	Cash		DRIP		Total Distribution
February 7, 2024	Class A	$	4,600	$	1,181	$	5,781
February 7, 2024	Class I	347		229		576
February 7, 2024	Class T	786		632		1,418

		$	5,733	$	2,042	$	7,775

The following tables summarize the daily distributions approved and authorized by the Board subsequent to December 31, 2023:


Authorization Date (1)	Common Stock	Daily Distribution Rate (1)		Annualized Distribution Per Share
January 15, 2024	Class A	$	0.00109290	$	0.40
January 15, 2024	Class I	$	0.00109290	$	0.40
January 15, 2024	Class T	$	0.00109290	$	0.40


Authorization Date (2)	Common Stock	Daily Distribution Rate (2)		Annualized Distribution Per Share
February 15, 2024	Class A	$	0.00109290	$	0.40
February 15, 2024	Class I	$	0.00109290	$	0.40
February 15, 2024	Class T	$	0.00109290	$	0.40


Authorization Date (3)	Common Stock	Daily Distribution Rate (3)		Annualized Distribution Per Share
March 5, 2024	Class A	$	0.00109290	$	0.40
March 5, 2024	Class I	$	0.00109290	$	0.40
March 5, 2024	Class T	$	0.00109290	$	0.40

(1)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on February 1, 2024 and ending on February 29, 2024. The distributions are calculated based on 366 days in the calendar year. The distributions declared for each record date in February 2024 will be paid in March 2024. The distributions are payable to stockholders from legally available funds therefor.

(2)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on March 1, 2024 and ending on March 31, 2024. The distributions will be calculated based on 366 days in the calendar year. The distributions declared for each record date in March 2024 will be paid in April 2024. The distributions will be payable to stockholders from legally available funds therefor.

(3)Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on April 1, 2024 and ending on April 30, 2024. The distributions will be calculated based on 366 days in the calendar year. The distributions declared for each record date in April 2024 will be paid in May 2024. The distributions will be payable to stockholders from legally available funds therefor.

Organization and Business Operations (Details)	12 Months Ended
Organization and Business Operations (Details)	Dec. 31, 2023
Operating Partnership
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest (as a percentage)	100.00%

Summary of Significant Accounting Policies (Share Repurchase Program) (Details)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Maximum number of shares available for repurchase during any calendar year, as percentage of common stock outstanding at end of prior year	5.00%
Period of notice required for changes to share repurchase program	30 days

Summary of Significant Accounting Policies (Reportable Segments) (Details)	12 Months Ended
	Dec. 31, 2023 segment
Accounting Policies [Abstract]
Number of reportable business segments	1

Summary of Significant Accounting Policies (Reconciliation of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 202,019	$ 12,917	$ 32,359	$ 53,174
Restricted cash	166	166	521	14,735
Cash, cash equivalents and restricted cash	$ 202,185	$ 13,083	$ 32,880	$ 67,909

Summary of Significant Accounting Policies (Investment In Real Estate) (Details)	Dec. 31, 2023
Building and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Building and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Furniture and Fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

Real Estate (Narrative) (Details)	12 Months Ended
Real Estate (Narrative) (Details)	Dec. 31, 2023 USD ($) property statisticalArea tenant acquistion	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Real Estate [Line Items]
Number of real estate properties acquired \| property	2
Number of asset acquisitions \| acquistion	2
Capitalized acquisition costs	$ 158,000
Proceeds from real estate dispositions and related notes receivable	270,306,000	$ 22,822,000	$ 1,338,709,000
Impairment loss	24,252,000	47,424,000	27,837,000
Impairment loss on goodwill	$ 4,010,000	$ 1,574,000	$ 671,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Impairment loss	Impairment loss	Impairment loss
In-place leases
Real Estate [Line Items]
Impairment of intangible assets	$ 1,130,000	$ 4,345,000
Above-market leases
Real Estate [Line Items]
Impairment of intangible assets	$ 260,000
Revenue \| Geographic Concentration Risk \| Houston-The Woodlands-Sugar Land, Texas MSA
Real Estate [Line Items]
Number of geographic concentration \| statisticalArea	1
Concentration risk, percentage	10.20%
Revenue \| Customer Concentration Risk \| One Tenant
Real Estate [Line Items]
Number of major tenants \| tenant	1
Revenue \| Customer Concentration Risk \| Post Acute Medical LLC and affiliates
Real Estate [Line Items]
Concentration risk, percentage	14.50%
2023 Real Estate Property Disposition, 1 \| Disposal Group, Disposed of by Sale, Not Discontinued Operations
Real Estate [Line Items]
Number of real estate properties owned \| property	3
Sale price of real estate dispositions	$ 271,107,000

Real Estate (Schedule of Consideration Transferred for Properties Acquired) (Details) - USD ($) $ in Thousands			12 Months Ended
	Sep. 27, 2023	Jun. 15, 2023	Dec. 31, 2023
Business Acquisition [Line Items]
Consideration transferred			$ 69,822
West Palm Beach Healthcare Facility
Business Acquisition [Line Items]
Ownership Percentage		100.00%
Consideration transferred		$ 9,920
Burr Ridge Healthcare Facility
Business Acquisition [Line Items]
Ownership Percentage	100.00%
Consideration transferred	$ 59,902

Real Estate (Schedule of Allocation of Acquisitions) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]
Total assets acquired	$ 69,822
In-place leases
Business Acquisition [Line Items]
Leases	9,767
Land
Business Acquisition [Line Items]
Property, plant and equipment acquired	6,892
Building and improvements
Business Acquisition [Line Items]
Property, plant and equipment acquired	51,337
Tenant improvements
Business Acquisition [Line Items]
Property, plant and equipment acquired	$ 1,826

Real Estate (Schedule of Rollforward of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Balance at beginning of year	$ 21,710	$ 23,284
Impairment losses	(4,010)	(1,574)	$ (671)
Balance at end of year	$ 17,700	$ 21,710	$ 23,284

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Discontinued Operations (Narrative) (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Jul. 30, 2021 USD ($)	Jul. 22, 2021 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 19, 2021 property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from real estate dispositions and related notes receivable			$ 270,306	$ 22,822	$ 1,338,709
Special cash dividend (in dollars per share) \| $ / shares		$ 1.75
Special cash distributions	$ 392,685
Discontinued Operations, Held-for-sale \| Data Centers
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of real estate properties owned \| property						29
Discontinued Operations, Disposed of by Sale \| Data Centers
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate sales price		$ 1,320,000
Proceeds from real estate dispositions and related notes receivable		$ 1,295,367

Discontinued Operations (Disposal Group Financials) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 22, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Gain on real estate dispositions		$ 0	$ 0	$ 395,801
Net income from discontinued operations attributable to common stockholders		0	0	401,444
Notes payable, principal amount outstanding	$ 450,806
Capital expenditures		$ 3,177	$ 8,440	25,405
Held-for-sale or Disposed of by Sale \| Data Centers
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Rental revenue				57,903
Lease termination revenue				7,075
Total revenue				64,978
Rental expenses				15,737
Depreciation and amortization				11,759
Total expenses				27,496
Interest and other expense, net				31,839
Income from discontinued operations				5,643
Gain on real estate dispositions				395,801
Net income from discontinued operations attributable to common stockholders				401,444
Capital expenditures				2,763
Discontinued Operations, Disposed of by Sale \| Data Centers
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Interest expense attributable to discontinued operations				$ 31,856
Debt extinguishment costs incurred	$ 23,738

Intangible Assets, Net (Schedule of Intangible Assets, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ 102,456	$ 90,239
Weighted average remaining useful life of intangible assets (in years)	7 years 8 months 12 days	8 years 9 months 18 days
Intangible assets, net of accumulated amortization	$ 134,999	$ 167,483
In-place leases
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ 95,325	$ 83,788
Weighted average remaining useful life of intangible assets (in years)	7 years 9 months 18 days	8 years 10 months 24 days
Intangible assets, net of accumulated amortization	$ 125,188	$ 155,365
Above-market leases
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ 7,131	$ 6,451
Weighted average remaining useful life of intangible assets (in years)	6 years 8 months 12 days	7 years 10 months 24 days
Intangible assets, net of accumulated amortization	$ 9,811	$ 12,118

Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Weighted average remaining useful life of intangible assets (in years)	7 years 8 months 12 days	8 years 9 months 18 days
Amortization of intangible assets	$ 23,766	$ 27,389	$ 23,157

Intangible Assets, Net (Schedule of Estimated Future Amortization Expense of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 20,351
2025	18,362
2026	16,815
2027	15,238
2028	13,704
Thereafter	50,529
Acquired intangible assets, net of accumulated amortization	$ 134,999	$ 167,483

Intangible Liabilities, Net (Schedule of Intangible Liabilities, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Intangible Lease Liabilities, Net [Abstract]
Accumulated amortization of below-market leases	$ 7,417	$ 5,923
Weighted average remaining life of below-market leases	7 years 4 months 24 days	8 years 4 months 24 days
Below-market leases, net of accumulated amortization	$ 10,452	$ 11,946

Intangible Liabilities, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Intangible Lease Liabilities, Net [Abstract]
Amortization of below-market leases	$ 1,494	$ 1,479	$ 1,322

Intangible Liabilities, Net (Schedule of Estimated Future Amortization of Intangible Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Intangible Lease Liabilities, Net [Abstract]
2024	$ 1,494
2025	1,494
2026	1,475
2027	1,450
2028	1,146
Thereafter	3,393
Acquired intangible liabilities, net	$ 10,452	$ 11,946

Leases (Schedule of Future Minimum Rent to Lessor from Operating Leases) (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 177,637
2025	173,816
2026	168,143
2027	165,189
2028	160,868
Thereafter	829,692
Total	$ 1,675,345

Leases (Schedule of Rent Payments from Lessee) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
2024	$ 2,746
2025	2,768
2026	2,715
2027	2,681
2028	2,692
Thereafter	104,764
Total undiscounted rental payments	118,366
Less imputed interest	(77,208)
Lease liabilities	$ 41,158	$ 41,554
Weighted average IBR	5.50%
Weighted average remaining lease term	36 years 6 months

Leases (Schedule of Lease Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 732	$ 531	$ 1,067
Rental expenses
Lessee, Lease, Description [Line Items]
Operating lease costs	2,727	2,246	1,846
Income from discontinued operations
Lessee, Lease, Description [Line Items]
Operating lease costs	0	0	414
General and administrative expenses
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 735	$ 741	$ 1,129

Other Assets (Schedule of Other Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $1,917 and $889, respectively	$ 2,271	$ 3,178
Leasing commissions, net of accumulated amortization of $191 and $167, respectively	593	775
Restricted cash	166	166
Tenant receivables	2,398	1,736
Straight-line rent receivable	53,248	62,457
Prepaid and other assets	4,089	3,865
Derivative assets	17,060	27,990
Total other assets	79,825	100,167
Deferred financing costs, related to the revolver portion of the credit facility, accumulated amortization	1,917	889
Leasing commissions, accumulated amortization	191	167
Amortization of deferred financing costs	1,665	1,679	$ 3,425
Revolving Line of Credit
Line of Credit Facility [Line Items]
Amortization of deferred financing costs	$ 1,027	$ 1,087	$ 1,430

Accounts Payable and Other Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 3,906	$ 5,387
Accrued interest expense	1,714	1,941
Accrued property taxes	3,687	2,421
Accrued personnel costs	4,425	3,940
Distributions payable to stockholders	7,782	7,719
Performance DSUs distributions payable	1,140	573
Tenant deposits	877	877
Deferred rental income	6,393	7,761
Derivative liabilities	457	0
Total accounts payable and other liabilities	$ 30,381	$ 30,619

Credit Facility (Schedule of Credit Facility) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Total credit facility, Weighted Average Contractual Rate	3.28%
Total credit facility, principal amount outstanding	$ 525,000	$ 583,000
Unamortized deferred financing costs related to credit facility term loans	(1,847)	(2,412)
Total credit facility, net of deferred financing costs	$ 523,153	580,588
Revolving Line of Credit \| Variable rate revolving line of credit
Line of Credit Facility [Line Items]
Total credit facility, Weighted Average Contractual Rate	0.00%
Total credit facility, principal amount outstanding	$ 0	8,000
Term Loan \| Variable rate term loans fixed through interest rate swaps
Line of Credit Facility [Line Items]
Total credit facility, Weighted Average Contractual Rate	3.28%
Total credit facility, principal amount outstanding	$ 525,000	485,000
Term Loan \| Variable rate term loans
Line of Credit Facility [Line Items]
Total credit facility, Weighted Average Contractual Rate	0.00%
Total credit facility, principal amount outstanding	$ 0	$ 90,000

Credit Facility (Narrative) (Details) - USD ($) $ in Thousands							12 Months Ended
	Dec. 19, 2023	Nov. 01, 2023	Sep. 26, 2023	Jul. 13, 2023	Apr. 13, 2023	Mar. 08, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Feb. 17, 2023
Line of Credit Facility [Line Items]
Payments on credit facility							$ 108,000	$ 762,000	$ 453,000
Proceeds from credit facility							50,000	$ 845,000	$ 15,000
2028 Term Loan \| Term Loan
Line of Credit Facility [Line Items]
Commitments available							275,000
Maximum borrowing capacity							$ 500,000
Fee percentage, average daily amount outstanding less than half of commitments							0.20%
Fee percentage, average daily amount outstanding more than half of commitments							0.15%
2024 Term Loan \| Term Loan
Line of Credit Facility [Line Items]
Commitments available							$ 250,000
Maximum borrowing capacity							$ 550,000
Minimum \| 2028 Term Loan \| Term Loan \| Base Rate
Line of Credit Facility [Line Items]
Margin range							0.25%
Minimum \| 2028 Term Loan \| Term Loan \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Line of Credit Facility [Line Items]
Margin range							1.25%
Maximum \| 2028 Term Loan \| Term Loan \| Base Rate
Line of Credit Facility [Line Items]
Margin range							0.90%
Maximum \| 2028 Term Loan \| Term Loan \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Line of Credit Facility [Line Items]
Margin range							1.90%
Revolving Line of Credit
Line of Credit Facility [Line Items]
Commitments available							$ 500,000
Maximum borrowing capacity							$ 1,000,000
Payments on credit facility	$ 42,000	$ 8,000				$ 8,000
Proceeds from credit facility			$ 50,000
Term Loan
Line of Credit Facility [Line Items]
Payments on credit facility	$ 30,000			$ 10,000	$ 10,000
Interest Rate Swap, Effective Date March 1, 2023
Line of Credit Facility [Line Items]
Notional amount										$ 40,000

Credit Facility (Schedule of Principal Payments Due on Credit Facility) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Extension
Debt Disclosure [Abstract]
2024	$ 250,000
2025	0
2026	0
2027	0
2028	275,000
Thereafter	0
Total	$ 525,000
2024 term loan, extension period	6 months
Number of extensions \| Extension	2

Fair Value (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Total credit facility, principal amount outstanding	$ 525,000	$ 583,000
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Accounts payable and other liabilities	Accounts payable and other liabilities

Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets:
Derivative assets	$ 17,060	$ 27,990
Derivative liabilities	457	0
Recurring basis
Assets:
Derivative assets	17,060	27,990
Total assets at fair value	17,060	27,990
Derivative liabilities	457
Total liabilities at fair value	457
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring basis
Assets:
Derivative assets	0	0
Total assets at fair value	0	0
Derivative liabilities	0
Total liabilities at fair value	0
Significant Other Observable Inputs (Level 2) \| Recurring basis
Assets:
Derivative assets	17,060	27,990
Total assets at fair value	17,060	27,990
Derivative liabilities	457
Total liabilities at fair value	457
Significant Unobservable Inputs (Level 3) \| Recurring basis
Assets:
Derivative assets	0	0
Total assets at fair value	0	$ 0
Derivative liabilities	0
Total liabilities at fair value	$ 0

- Definition

Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480493/946-210-55-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

+ Details

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

+ Details

Fair Value (Schedule of Fair Value, Real Estate Assets Measured on Non-Recurring Basis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 1,628,652	$ 1,880,082
Impairment loss on real estate	20,758	29,010
Impairment loss on goodwill	4,010	1,574	$ 671
In-place leases
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of intangible assets	1,130	4,345
Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	37,600
Impairment loss on real estate	19,628
Impairment loss on goodwill	792
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	0
Significant Other Observable Inputs (Level 2) \| Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	21,400	$ 1,400
Significant Unobservable Inputs (Level 3) \| Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 16,200

Fair Value (Summary of Significant Unobservable Inputs) (Details) - Significant Unobservable Inputs (Level 3)	Dec. 31, 2023 $ / sqft
Overall capitalization rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Real estate assets, measurement input	0.085
Market rent per square foot \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Real estate assets, measurement input	45.00
Range of comparable sale price per square foot \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Real estate assets, measurement input	60.86
Range of comparable sale price per square foot \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Real estate assets, measurement input	98.04

Derivative Instruments and Hedging Activities (Narrative) (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Additional gain expected to be reclassified from AOCI into earnings during next twelve months	$ 14,114

Derivative Instruments and Hedging Activities (Schedule of the Notional Amount and Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Fair Value of Asset	$ 17,060	$ 27,990
Fair Value of Liability	(457)
Interest rate swaps \| Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Outstanding Notional Amount	525,000	485,000
Interest rate swaps \| Designated as Hedging Instrument \| Other Assets
Derivatives, Fair Value [Line Items]
Fair Value of Asset	17,060	$ 27,990
Interest rate swaps \| Designated as Hedging Instrument \| Accounts Payable and Other Liabilities
Derivatives, Fair Value [Line Items]
Fair Value of Liability	$ (457)

Derivative Instruments and Hedging Activities (Schedule of Income and Losses Recognized on Derivative Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives			$ 5,919
Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)			(9,678)
Interest and other income	$ 23,110	$ 24,077
Continuing Operations
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income			37,625
Discontinued Operations, Disposed of by Sale \| Data Centers
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income			(401,444)
Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives	5,293	32,317
Interest rate swaps \| Continuing Operations
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives			5,956
Interest rate swaps \| Discontinued Operations, Disposed of by Sale \| Data Centers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Recognized in Other Comprehensive Income on Derivatives			(37)
Interest rate swaps \| Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)	$ 16,680	$ (520)
Interest rate swaps \| Interest expense \| Continuing Operations
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)			(8,031)
Interest rate swaps \| Income from discontinued operations \| Discontinued Operations, Disposed of by Sale \| Data Centers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Income (Loss) Reclassified From Accumulated Other Comprehensive Income to Net Income (Loss)			$ (1,647)

Derivative Instruments and Hedging Activities (Schedule of Offsetting of Derivative Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross Amounts of Recognized Assets	$ 17,060	$ 27,990
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	17,060	27,990
Gross Amounts Not Offset in the Balance Sheet, Financial Instruments Collateral	(457)	0
Gross Amounts Not Offset in the Balance Sheet, Cash Collateral	0	0
Net Amount	$ 16,603	$ 27,990

- Definition

Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480493/946-210-55-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

+ Details

Derivative Instruments and Hedging Activities (Schedule of Offsetting of Derivative Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross Amounts of Recognized Liabilities	$ 457
Gross Amounts Offset in the Balance Sheet	0
Net Amounts of Liabilities Presented in the Balance Sheet	457	$ 0
Financial Instruments Collateral	(457)
Cash Collateral	0
Net Amount	$ 0

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

+ Details

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Thousands						12 Months Ended
	Mar. 05, 2024 $ / shares	Feb. 15, 2024 $ / shares	Feb. 07, 2024 USD ($)	Jan. 15, 2024 $ / shares	Jan. 08, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Class of Stock [Line Items]
Distributions declared per common share (in dollars per share) \| $ / shares						$ 0.40	$ 0.40	$ 2.19
Special cash distribution per common share (in dollars per share) \| $ / shares							$ 1.75
Issuance of common stock under the distribution reinvestment plan						$ 24,751	$ 24,834	$ 27,584
Stock Redeemed or Called During Period, Percentage of Shares Outstanding						0.0067	0.0050
Repurchase of common stock						$ 12,374	$ 9,217	9,528
Subsequent Event
Class of Stock [Line Items]
Distributions paid			$ 7,775		$ 7,782
Cash			5,733		5,729
Issuance of common stock under the distribution reinvestment plan			2,042		2,053
Common Stock
Class of Stock [Line Items]
Issuance of common stock under the distribution reinvestment plan						$ 30	$ 30	$ 33
Repurchase of common stock (in shares) \| shares						1,513,997	1,123,183	1,133,901
Repurchase of common stock						$ 15	$ 11	$ 11
Class A, I and T Shares \| Common Stock
Class of Stock [Line Items]
Repurchase of common stock (in shares) \| shares						1,513,997	1,123,183
Repurchase of common stock						$ 12,374	$ 9,217
Repurchase of common stock, average price per share (in dollars per share) \| $ / shares						$ 8.17	$ 8.21
Class A \| Subsequent Event
Class of Stock [Line Items]
Distributions declared per common share (in dollars per share) \| $ / shares	$ 0.00109290	$ 0.00109290		$ 0.00109290
Distributions paid			5,781		5,787
Cash			4,600		4,597
Issuance of common stock under the distribution reinvestment plan			1,181		1,190
Class A \| Common Stock
Class of Stock [Line Items]
Repurchase of common stock (in shares) \| shares						1,182,006	981,772
Class I \| Subsequent Event
Class of Stock [Line Items]
Distributions declared per common share (in dollars per share) \| $ / shares	0.00109290	0.00109290		0.00109290
Distributions paid			576		576
Cash			347		347
Issuance of common stock under the distribution reinvestment plan			229		229
Class I \| Common Stock
Class of Stock [Line Items]
Repurchase of common stock (in shares) \| shares						105,660	31,666
Class T \| Subsequent Event
Class of Stock [Line Items]
Distributions declared per common share (in dollars per share) \| $ / shares	$ 0.00109290	$ 0.00109290		$ 0.00109290
Distributions paid			1,418		1,419
Cash			786		785
Issuance of common stock under the distribution reinvestment plan			$ 632		$ 634
Class T \| Common Stock
Class of Stock [Line Items]
Repurchase of common stock (in shares) \| shares						226,331	109,745

Stockholders' Equity (Amounts Recognized in AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning	$ 1,555,095	$ 1,601,130	$ 1,653,873
Other comprehensive income (loss)	(11,387)	32,837	15,597
Balance ending	1,494,435	1,555,095	1,601,130
Unrealized Income (Loss) on Derivative Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance beginning	27,990	(4,847)	(20,444)
Other comprehensive income before reclassification	5,293	32,317	5,919
Amount of loss reclassified from accumulated other comprehensive loss to net income (loss)	(16,680)	520	9,678
Other comprehensive income (loss)	(11,387)	32,837	15,597
Balance ending	$ 16,603	$ 27,990	$ (4,847)

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482739/220-10-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

Stockholders' Equity (Reclassifications Out of AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest rate swap contracts - continuing operations	$ 23,110	$ 24,077
Interest rate swap contracts - discontinued operations	0	0	$ (401,444)
Interest rate swap contracts	(24,042)	7,978	(402,660)
Interest rate swaps \| (Income) Loss Amounts Reclassified from Accumulated Other Comprehensive Income to Net Income (Loss) \| Reclassification out of Accumulated Other Comprehensive Income (Loss)
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest rate swap contracts - continuing operations	(16,680)	520	8,031
Interest rate swap contracts - discontinued operations	0	0	1,647
Interest rate swap contracts	$ (16,680)	$ 520	$ 9,678

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
Earnings Per Share (Details) - shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Diluted earnings per share outstanding adjustment (in shares)	1,847		968
Anti-dilutive shares excluded from computation of earnings per share (in shares)		1,341

Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
Stock-based Compensation (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 06, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 6,284	$ 4,180	$ 2,379
Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of authorized and reserved shares of common stock under plan (in shares)				5,000,000
Restricted Class A Common Stock and Performance DSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, weighted average period of recognition	1 year 11 months 8 days
Restricted Class A Common Stock and Performance DSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 6,807	6,834
Fair value of nonvested shares of restricted common stock	$ 15,098	$ 11,703

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Stock-based Compensation (Schedule of Nonvested Shares of Restricted Common Stock Activity) (Details) - Restricted Class A Common Stock and Performance DSUs	12 Months Ended
	Dec. 31, 2023 shares
Summary of Restricted Common Stock Activity, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	1,423,690
Granted (in shares)	793,718
Vested (in shares)	(160,453)
Forfeited (in shares)	(38,451)
Ending balance (in shares)	2,018,504

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Impact related to uncertain tax positions from the results of operations	$ 0	$ 0	$ 0
Interest expense or penalties related to unrecognized tax benefits	$ 0

Income Taxes (Schedule of Characterization of Distributions Paid to Stockholders) (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Common Class A, I, T and T2 Shares
Income Taxes [Line Items]
Ordinary dividends (as a percent)	61.41%	40.94%	27.91%
Capital gain distributions (as a percent)	0.00%	0.00%	0.00%
Nontaxable distributions (as a percent)	38.59%	59.06%	72.09%
Total (as a percent)	100.00%	100.00%	100.00%
Special Dividends
Income Taxes [Line Items]
Ordinary dividends (as a percent)	0.00%	0.00%	12.39%
Capital gain distributions (as a percent)	0.00%	0.00%	86.66%
Nontaxable distributions (as a percent)	0.00%	0.00%	0.95%
Total (as a percent)	0.00%	0.00%	100.00%

Subsequent Events (Details) - USD ($)								1 Months Ended			12 Months Ended
Subsequent Events (Details) - USD ($)	Mar. 05, 2024	Feb. 26, 2024	Feb. 15, 2024	Feb. 07, 2024	Jan. 31, 2024	Jan. 15, 2024	Jan. 08, 2024	Apr. 30, 2024	Mar. 31, 2024	Feb. 29, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock issued through distribution reinvestment plan											$ 24,751,000	$ 24,834,000	$ 27,584,000
Distributions declared per common share (in dollars per share)											$ 0.40	$ 0.40	$ 2.19
Proceeds from real estate dispositions and related notes receivable											$ 270,306,000	$ 22,822,000	$ 1,338,709,000
Forecast \| Class A, I and T shares
Subsequent Event [Line Items]
Number of days, distribution calculation								366 days
Subsequent Event
Subsequent Event [Line Items]
Cash				$ 5,733,000			$ 5,729,000
Common stock issued through distribution reinvestment plan				2,042,000			2,053,000
Distributions paid				7,775,000			7,782,000
Proceeds from real estate dispositions and related notes receivable					$ 1,407,000
Subsequent Event \| Brownsburg Healthcare Facility
Subsequent Event [Line Items]
Membership interests acquired percentage		100.00%
Cash paid in transaction		$ 39,063,000
Subsequent Event \| Disposal Group, Disposed of by Sale, Not Discontinued Operations \| New Bedford Healthcare Facility
Subsequent Event [Line Items]
Sale price of real estate dispositions					$ 1,500,000
Subsequent Event \| Class A
Subsequent Event [Line Items]
Cash				4,600,000			4,597,000
Common stock issued through distribution reinvestment plan				1,181,000			1,190,000
Distributions paid				5,781,000			5,787,000
Distributions declared per common share (in dollars per share)	$ 0.00109290		$ 0.00109290			$ 0.00109290
Annualized distribution per share (in dollars per share)	0.40		0.40			0.40
Subsequent Event \| Class I
Subsequent Event [Line Items]
Cash				347,000			347,000
Common stock issued through distribution reinvestment plan				229,000			229,000
Distributions paid				576,000			576,000
Distributions declared per common share (in dollars per share)	0.00109290		0.00109290			0.00109290
Annualized distribution per share (in dollars per share)	0.40		0.40			0.40
Subsequent Event \| Class T
Subsequent Event [Line Items]
Cash				786,000			785,000
Common stock issued through distribution reinvestment plan				632,000			634,000
Distributions paid				$ 1,418,000			$ 1,419,000
Distributions declared per common share (in dollars per share)	0.00109290		0.00109290			0.00109290
Annualized distribution per share (in dollars per share)	$ 0.40		$ 0.40			$ 0.40
Subsequent Event \| Class A, I and T shares
Subsequent Event [Line Items]
Number of days, distribution calculation										366 days
Subsequent Event \| Forecast \| Class A, I and T shares
Subsequent Event [Line Items]
Number of days, distribution calculation									366 days

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 0
Initial Cost, Land	165,071
Initial Cost, Buildings and Improvements	1,631,875
Cost Capitalized Subsequent to Acquisition	58,862
Gross Amount Carried at Close of Period, Land	157,821
Gross Amount Carried at Close of Period, Buildings and Improvements	1,697,987
Gross Amount Carried at Close of Period, Total	1,855,808	$ 2,089,200	$ 2,015,330	$ 2,890,958
Accumulated Depreciation	227,156	$ 209,118	$ 165,784	$ 197,134
Houston Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	762
Initial Cost, Buildings and Improvements	2,970
Cost Capitalized Subsequent to Acquisition	106
Gross Amount Carried at Close of Period, Land	762
Gross Amount Carried at Close of Period, Buildings and Improvements	3,076
Gross Amount Carried at Close of Period, Total	3,838
Accumulated Depreciation	960
Cincinnati Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	356
Initial Cost, Buildings and Improvements	3,167
Cost Capitalized Subsequent to Acquisition	114
Gross Amount Carried at Close of Period, Land	356
Gross Amount Carried at Close of Period, Buildings and Improvements	3,281
Gross Amount Carried at Close of Period, Total	3,637
Accumulated Depreciation	907
Winston-Salem Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	684
Initial Cost, Buildings and Improvements	4,903
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	684
Gross Amount Carried at Close of Period, Buildings and Improvements	4,903
Gross Amount Carried at Close of Period, Total	5,587
Accumulated Depreciation	1,322
Stoughton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,049
Initial Cost, Buildings and Improvements	19,991
Cost Capitalized Subsequent to Acquisition	(13,054)
Gross Amount Carried at Close of Period, Land	2,018
Gross Amount Carried at Close of Period, Buildings and Improvements	8,968
Gross Amount Carried at Close of Period, Total	10,986
Accumulated Depreciation	0
Fort Worth Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	8,297
Initial Cost, Buildings and Improvements	35,615
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	8,297
Gross Amount Carried at Close of Period, Buildings and Improvements	35,615
Gross Amount Carried at Close of Period, Total	43,912
Accumulated Depreciation	8,443
Fort Worth Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	367
Initial Cost, Buildings and Improvements	1,587
Cost Capitalized Subsequent to Acquisition	201
Gross Amount Carried at Close of Period, Land	367
Gross Amount Carried at Close of Period, Buildings and Improvements	1,788
Gross Amount Carried at Close of Period, Total	2,155
Accumulated Depreciation	665
Winter Haven Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	2,805
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	2,805
Gross Amount Carried at Close of Period, Total	2,805
Accumulated Depreciation	697
Overland Park Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,558
Initial Cost, Buildings and Improvements	20,549
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,558
Gross Amount Carried at Close of Period, Buildings and Improvements	20,549
Gross Amount Carried at Close of Period, Total	22,107
Accumulated Depreciation	4,794
Clarion Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	462
Initial Cost, Buildings and Improvements	5,377
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	462
Gross Amount Carried at Close of Period, Buildings and Improvements	5,377
Gross Amount Carried at Close of Period, Total	5,839
Accumulated Depreciation	1,553
Webster Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,858
Initial Cost, Buildings and Improvements	20,140
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,858
Gross Amount Carried at Close of Period, Buildings and Improvements	20,140
Gross Amount Carried at Close of Period, Total	21,998
Accumulated Depreciation	4,511
Augusta Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	556
Initial Cost, Buildings and Improvements	14,401
Cost Capitalized Subsequent to Acquisition	103
Gross Amount Carried at Close of Period, Land	556
Gross Amount Carried at Close of Period, Buildings and Improvements	14,504
Gross Amount Carried at Close of Period, Total	15,060
Accumulated Depreciation	3,455
Cincinnati Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	446
Initial Cost, Buildings and Improvements	10,239
Cost Capitalized Subsequent to Acquisition	4
Gross Amount Carried at Close of Period, Land	446
Gross Amount Carried at Close of Period, Buildings and Improvements	10,243
Gross Amount Carried at Close of Period, Total	10,689
Accumulated Depreciation	2,304
Florence Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	650
Initial Cost, Buildings and Improvements	9,919
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	650
Gross Amount Carried at Close of Period, Buildings and Improvements	9,919
Gross Amount Carried at Close of Period, Total	10,569
Accumulated Depreciation	2,223
Oakland Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	229
Initial Cost, Buildings and Improvements	5,416
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	229
Gross Amount Carried at Close of Period, Buildings and Improvements	5,416
Gross Amount Carried at Close of Period, Total	5,645
Accumulated Depreciation	1,400
Wyomissing Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,504
Initial Cost, Buildings and Improvements	20,193
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,504
Gross Amount Carried at Close of Period, Buildings and Improvements	20,193
Gross Amount Carried at Close of Period, Total	21,697
Accumulated Depreciation	4,615
Luling Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	824
Initial Cost, Buildings and Improvements	7,530
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	824
Gross Amount Carried at Close of Period, Buildings and Improvements	7,530
Gross Amount Carried at Close of Period, Total	8,354
Accumulated Depreciation	1,712
Omaha Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,259
Initial Cost, Buildings and Improvements	9,796
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,259
Gross Amount Carried at Close of Period, Buildings and Improvements	9,796
Gross Amount Carried at Close of Period, Total	11,055
Accumulated Depreciation	2,113
Sherman Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,679
Initial Cost, Buildings and Improvements	23,926
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,679
Gross Amount Carried at Close of Period, Buildings and Improvements	23,926
Gross Amount Carried at Close of Period, Total	25,605
Accumulated Depreciation	5,051
Sherman Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	214
Initial Cost, Buildings and Improvements	3,209
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	214
Gross Amount Carried at Close of Period, Buildings and Improvements	3,209
Gross Amount Carried at Close of Period, Total	3,423
Accumulated Depreciation	683
Fort Worth Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,120
Initial Cost, Buildings and Improvements	9,312
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,120
Gross Amount Carried at Close of Period, Buildings and Improvements	9,312
Gross Amount Carried at Close of Period, Total	12,432
Accumulated Depreciation	1,970
Oklahoma City Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,626
Initial Cost, Buildings and Improvements	30,509
Cost Capitalized Subsequent to Acquisition	99
Gross Amount Carried at Close of Period, Land	4,626
Gross Amount Carried at Close of Period, Buildings and Improvements	30,608
Gross Amount Carried at Close of Period, Total	35,234
Accumulated Depreciation	6,663
Oklahoma City Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	991
Initial Cost, Buildings and Improvements	8,366
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	991
Gross Amount Carried at Close of Period, Buildings and Improvements	8,366
Gross Amount Carried at Close of Period, Total	9,357
Accumulated Depreciation	1,942
Edmond Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	796
Initial Cost, Buildings and Improvements	3,199
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	796
Gross Amount Carried at Close of Period, Buildings and Improvements	3,199
Gross Amount Carried at Close of Period, Total	3,995
Accumulated Depreciation	749
Oklahoma City Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	452
Initial Cost, Buildings and Improvements	1,081
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	452
Gross Amount Carried at Close of Period, Buildings and Improvements	1,081
Gross Amount Carried at Close of Period, Total	1,533
Accumulated Depreciation	260
Oklahoma City Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	368
Initial Cost, Buildings and Improvements	2,344
Cost Capitalized Subsequent to Acquisition	28
Gross Amount Carried at Close of Period, Land	368
Gross Amount Carried at Close of Period, Buildings and Improvements	2,372
Gross Amount Carried at Close of Period, Total	2,740
Accumulated Depreciation	549
Newcastle Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	412
Initial Cost, Buildings and Improvements	1,173
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	412
Gross Amount Carried at Close of Period, Buildings and Improvements	1,173
Gross Amount Carried at Close of Period, Total	1,585
Accumulated Depreciation	281
Oklahoma City Healthcare Facility V
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	541
Initial Cost, Buildings and Improvements	12,445
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	541
Gross Amount Carried at Close of Period, Buildings and Improvements	12,445
Gross Amount Carried at Close of Period, Total	12,986
Accumulated Depreciation	2,891
Rancho Mirage Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,724
Initial Cost, Buildings and Improvements	7,626
Cost Capitalized Subsequent to Acquisition	29,843
Gross Amount Carried at Close of Period, Land	2,725
Gross Amount Carried at Close of Period, Buildings and Improvements	37,468
Gross Amount Carried at Close of Period, Total	40,193
Accumulated Depreciation	5,035
Oklahoma City Healthcare Facility VI
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	896
Initial Cost, Buildings and Improvements	3,684
Cost Capitalized Subsequent to Acquisition	84
Gross Amount Carried at Close of Period, Land	896
Gross Amount Carried at Close of Period, Buildings and Improvements	3,768
Gross Amount Carried at Close of Period, Total	4,664
Accumulated Depreciation	873
Oklahoma City Healthcare Facility VII
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,203
Initial Cost, Buildings and Improvements	32,380
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,203
Gross Amount Carried at Close of Period, Buildings and Improvements	32,380
Gross Amount Carried at Close of Period, Total	35,583
Accumulated Depreciation	6,408
Las Vegas Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,614
Initial Cost, Buildings and Improvements	639
Cost Capitalized Subsequent to Acquisition	22,091
Gross Amount Carried at Close of Period, Land	2,895
Gross Amount Carried at Close of Period, Buildings and Improvements	22,449
Gross Amount Carried at Close of Period, Total	25,344
Accumulated Depreciation	3,577
Oklahoma City Healthcare Facility VIII
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,002
Initial Cost, Buildings and Improvements	15,384
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,002
Gross Amount Carried at Close of Period, Buildings and Improvements	15,384
Gross Amount Carried at Close of Period, Total	17,386
Accumulated Depreciation	3,003
Marlton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	57,154
Cost Capitalized Subsequent to Acquisition	5
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	57,159
Gross Amount Carried at Close of Period, Total	57,159
Accumulated Depreciation	10,185
Grand Rapids Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,533
Initial Cost, Buildings and Improvements	39,487
Cost Capitalized Subsequent to Acquisition	1,554
Gross Amount Carried at Close of Period, Land	2,533
Gross Amount Carried at Close of Period, Buildings and Improvements	41,041
Gross Amount Carried at Close of Period, Total	43,574
Accumulated Depreciation	8,282
Corpus Christi Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	975
Initial Cost, Buildings and Improvements	4,963
Cost Capitalized Subsequent to Acquisition	793
Gross Amount Carried at Close of Period, Land	1,002
Gross Amount Carried at Close of Period, Buildings and Improvements	5,729
Gross Amount Carried at Close of Period, Total	6,731
Accumulated Depreciation	1,150
Aurora Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	973
Initial Cost, Buildings and Improvements	9,632
Cost Capitalized Subsequent to Acquisition	19
Gross Amount Carried at Close of Period, Land	973
Gross Amount Carried at Close of Period, Buildings and Improvements	9,651
Gross Amount Carried at Close of Period, Total	10,624
Accumulated Depreciation	1,768
Allen Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	857
Initial Cost, Buildings and Improvements	20,582
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	857
Gross Amount Carried at Close of Period, Buildings and Improvements	20,582
Gross Amount Carried at Close of Period, Total	21,439
Accumulated Depreciation	3,763
Austin Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,368
Initial Cost, Buildings and Improvements	32,039
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,368
Gross Amount Carried at Close of Period, Buildings and Improvements	32,039
Gross Amount Carried at Close of Period, Total	33,407
Accumulated Depreciation	5,858
Beaumont Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	946
Initial Cost, Buildings and Improvements	8,372
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	946
Gross Amount Carried at Close of Period, Buildings and Improvements	8,372
Gross Amount Carried at Close of Period, Total	9,318
Accumulated Depreciation	1,539
San Antonio Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,813
Initial Cost, Buildings and Improvements	11,706
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,813
Gross Amount Carried at Close of Period, Buildings and Improvements	11,706
Gross Amount Carried at Close of Period, Total	13,519
Accumulated Depreciation	2,076
Silverdale Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,530
Initial Cost, Buildings and Improvements	7,506
Cost Capitalized Subsequent to Acquisition	48
Gross Amount Carried at Close of Period, Land	1,530
Gross Amount Carried at Close of Period, Buildings and Improvements	7,554
Gross Amount Carried at Close of Period, Total	9,084
Accumulated Depreciation	1,469
Silverdale Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,542
Initial Cost, Buildings and Improvements	4,981
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,542
Gross Amount Carried at Close of Period, Buildings and Improvements	4,981
Gross Amount Carried at Close of Period, Total	6,523
Accumulated Depreciation	1,052
Saginaw Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,251
Initial Cost, Buildings and Improvements	15,878
Cost Capitalized Subsequent to Acquisition	235
Gross Amount Carried at Close of Period, Land	1,251
Gross Amount Carried at Close of Period, Buildings and Improvements	16,113
Gross Amount Carried at Close of Period, Total	17,364
Accumulated Depreciation	3,519
Carrollton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,995
Initial Cost, Buildings and Improvements	5,870
Cost Capitalized Subsequent to Acquisition	39
Gross Amount Carried at Close of Period, Land	1,995
Gross Amount Carried at Close of Period, Buildings and Improvements	5,909
Gross Amount Carried at Close of Period, Total	7,904
Accumulated Depreciation	943
Katy Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,443
Initial Cost, Buildings and Improvements	12,114
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,443
Gross Amount Carried at Close of Period, Buildings and Improvements	12,114
Gross Amount Carried at Close of Period, Total	13,557
Accumulated Depreciation	1,742
Indianola Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	330
Initial Cost, Buildings and Improvements	5,698
Cost Capitalized Subsequent to Acquisition	67
Gross Amount Carried at Close of Period, Land	330
Gross Amount Carried at Close of Period, Buildings and Improvements	5,765
Gross Amount Carried at Close of Period, Total	6,095
Accumulated Depreciation	828
Indianola Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	709
Initial Cost, Buildings and Improvements	6,061
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	709
Gross Amount Carried at Close of Period, Buildings and Improvements	6,061
Gross Amount Carried at Close of Period, Total	6,770
Accumulated Depreciation	904
Benton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	19,048
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	19,048
Gross Amount Carried at Close of Period, Total	19,048
Accumulated Depreciation	2,694
Benton Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	1,647
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	1,647
Gross Amount Carried at Close of Period, Total	1,647
Accumulated Depreciation	259
Bryant Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	930
Initial Cost, Buildings and Improvements	3,539
Cost Capitalized Subsequent to Acquisition	57
Gross Amount Carried at Close of Period, Land	930
Gross Amount Carried at Close of Period, Buildings and Improvements	3,596
Gross Amount Carried at Close of Period, Total	4,526
Accumulated Depreciation	554
Hot Springs Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	384
Initial Cost, Buildings and Improvements	2,077
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	384
Gross Amount Carried at Close of Period, Buildings and Improvements	2,077
Gross Amount Carried at Close of Period, Total	2,461
Accumulated Depreciation	334
Clive Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	336
Initial Cost, Buildings and Improvements	22,332
Cost Capitalized Subsequent to Acquisition	158
Gross Amount Carried at Close of Period, Land	336
Gross Amount Carried at Close of Period, Buildings and Improvements	22,490
Gross Amount Carried at Close of Period, Total	22,826
Accumulated Depreciation	3,637
Valdosta Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	659
Initial Cost, Buildings and Improvements	5,626
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	659
Gross Amount Carried at Close of Period, Buildings and Improvements	5,626
Gross Amount Carried at Close of Period, Total	6,285
Accumulated Depreciation	907
Valdosta Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	471
Initial Cost, Buildings and Improvements	2,780
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	471
Gross Amount Carried at Close of Period, Buildings and Improvements	2,780
Gross Amount Carried at Close of Period, Total	3,251
Accumulated Depreciation	455
Bryant Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	647
Initial Cost, Buildings and Improvements	3,364
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	647
Gross Amount Carried at Close of Period, Buildings and Improvements	3,364
Gross Amount Carried at Close of Period, Total	4,011
Accumulated Depreciation	419
Laredo Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	12,137
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	12,137
Gross Amount Carried at Close of Period, Total	12,137
Accumulated Depreciation	1,412
Laredo Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	23,677
Cost Capitalized Subsequent to Acquisition	83
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	23,760
Gross Amount Carried at Close of Period, Total	23,760
Accumulated Depreciation	2,816
Poplar Bluff Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	13,515
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	13,515
Gross Amount Carried at Close of Period, Total	13,515
Accumulated Depreciation	1,579
Tucson Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	5,998
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	5,998
Gross Amount Carried at Close of Period, Total	5,998
Accumulated Depreciation	704
Akron Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,503
Initial Cost, Buildings and Improvements	38,512
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,503
Gross Amount Carried at Close of Period, Buildings and Improvements	38,512
Gross Amount Carried at Close of Period, Total	42,015
Accumulated Depreciation	4,320
Akron Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,085
Initial Cost, Buildings and Improvements	10,277
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,085
Gross Amount Carried at Close of Period, Buildings and Improvements	10,277
Gross Amount Carried at Close of Period, Total	11,362
Accumulated Depreciation	1,385
Akron Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,206
Initial Cost, Buildings and Improvements	26,044
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,206
Gross Amount Carried at Close of Period, Buildings and Improvements	26,044
Gross Amount Carried at Close of Period, Total	28,250
Accumulated Depreciation	2,823
Alexandria Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	5,076
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	5,076
Gross Amount Carried at Close of Period, Total	5,076
Accumulated Depreciation	550
Appleton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	414
Initial Cost, Buildings and Improvements	1,900
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	414
Gross Amount Carried at Close of Period, Buildings and Improvements	1,900
Gross Amount Carried at Close of Period, Total	2,314
Accumulated Depreciation	274
Austin Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,229
Initial Cost, Buildings and Improvements	7,534
Cost Capitalized Subsequent to Acquisition	(2,807)
Gross Amount Carried at Close of Period, Land	2,195
Gross Amount Carried at Close of Period, Buildings and Improvements	5,761
Gross Amount Carried at Close of Period, Total	7,956
Accumulated Depreciation	641
Bellevue Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	567
Initial Cost, Buildings and Improvements	1,269
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	567
Gross Amount Carried at Close of Period, Buildings and Improvements	1,269
Gross Amount Carried at Close of Period, Total	1,836
Accumulated Depreciation	190
Bonita Springs Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,199
Initial Cost, Buildings and Improvements	4,373
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,199
Gross Amount Carried at Close of Period, Buildings and Improvements	4,373
Gross Amount Carried at Close of Period, Total	5,572
Accumulated Depreciation	487
Bridgeton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	39,740
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	39,740
Gross Amount Carried at Close of Period, Total	39,740
Accumulated Depreciation	4,289
Covington Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,238
Initial Cost, Buildings and Improvements	16,635
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,238
Gross Amount Carried at Close of Period, Buildings and Improvements	16,635
Gross Amount Carried at Close of Period, Total	18,873
Accumulated Depreciation	1,786
Crestview Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	400
Initial Cost, Buildings and Improvements	1,536
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	400
Gross Amount Carried at Close of Period, Buildings and Improvements	1,536
Gross Amount Carried at Close of Period, Total	1,936
Accumulated Depreciation	191
Dallas Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	6,072
Initial Cost, Buildings and Improvements	27,457
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	6,072
Gross Amount Carried at Close of Period, Buildings and Improvements	27,457
Gross Amount Carried at Close of Period, Total	33,529
Accumulated Depreciation	2,900
De Pere Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	615
Initial Cost, Buildings and Improvements	1,596
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	615
Gross Amount Carried at Close of Period, Buildings and Improvements	1,596
Gross Amount Carried at Close of Period, Total	2,211
Accumulated Depreciation	231
Denver Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,586
Initial Cost, Buildings and Improvements	32,363
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,586
Gross Amount Carried at Close of Period, Buildings and Improvements	32,363
Gross Amount Carried at Close of Period, Total	35,949
Accumulated Depreciation	3,525
El Segundo Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,659
Initial Cost, Buildings and Improvements	9,016
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,659
Gross Amount Carried at Close of Period, Buildings and Improvements	9,016
Gross Amount Carried at Close of Period, Total	11,675
Accumulated Depreciation	981
Fairlea Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	139
Initial Cost, Buildings and Improvements	1,910
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	139
Gross Amount Carried at Close of Period, Buildings and Improvements	1,910
Gross Amount Carried at Close of Period, Total	2,049
Accumulated Depreciation	220
Fayetteville Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	485
Initial Cost, Buildings and Improvements	24,855
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	485
Gross Amount Carried at Close of Period, Buildings and Improvements	24,855
Gross Amount Carried at Close of Period, Total	25,340
Accumulated Depreciation	2,669
Fort Myers Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,153
Initial Cost, Buildings and Improvements	2,387
Cost Capitalized Subsequent to Acquisition	(562)
Gross Amount Carried at Close of Period, Land	2,012
Gross Amount Carried at Close of Period, Buildings and Improvements	1,966
Gross Amount Carried at Close of Period, Total	3,978
Accumulated Depreciation	36
Fort Myers Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,557
Initial Cost, Buildings and Improvements	11,064
Cost Capitalized Subsequent to Acquisition	(2,304)
Gross Amount Carried at Close of Period, Land	3,272
Gross Amount Carried at Close of Period, Buildings and Improvements	9,045
Gross Amount Carried at Close of Period, Total	12,317
Accumulated Depreciation	152
Fort Walton Beach Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	385
Initial Cost, Buildings and Improvements	3,182
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	385
Gross Amount Carried at Close of Period, Buildings and Improvements	3,182
Gross Amount Carried at Close of Period, Total	3,567
Accumulated Depreciation	363
Frankfort Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	342
Initial Cost, Buildings and Improvements	950
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	342
Gross Amount Carried at Close of Period, Buildings and Improvements	950
Gross Amount Carried at Close of Period, Total	1,292
Accumulated Depreciation	122
Frisco Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	22,114
Cost Capitalized Subsequent to Acquisition	4,790
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	26,904
Gross Amount Carried at Close of Period, Total	26,904
Accumulated Depreciation	3,884
Goshen Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	383
Initial Cost, Buildings and Improvements	5,355
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	383
Gross Amount Carried at Close of Period, Buildings and Improvements	5,355
Gross Amount Carried at Close of Period, Total	5,738
Accumulated Depreciation	636
Hammond Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,693
Initial Cost, Buildings and Improvements	23,750
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,693
Gross Amount Carried at Close of Period, Buildings and Improvements	23,750
Gross Amount Carried at Close of Period, Total	26,443
Accumulated Depreciation	2,648
Hammond Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	950
Initial Cost, Buildings and Improvements	12,147
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	950
Gross Amount Carried at Close of Period, Buildings and Improvements	12,147
Gross Amount Carried at Close of Period, Total	13,097
Accumulated Depreciation	1,339
Henderson Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	839
Initial Cost, Buildings and Improvements	2,390
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	839
Gross Amount Carried at Close of Period, Buildings and Improvements	2,390
Gross Amount Carried at Close of Period, Total	3,229
Accumulated Depreciation	285
Houston Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	752
Initial Cost, Buildings and Improvements	5,832
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	752
Gross Amount Carried at Close of Period, Buildings and Improvements	5,832
Gross Amount Carried at Close of Period, Total	6,584
Accumulated Depreciation	631
Howard Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	529
Initial Cost, Buildings and Improvements	1,818
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	529
Gross Amount Carried at Close of Period, Buildings and Improvements	1,818
Gross Amount Carried at Close of Period, Total	2,347
Accumulated Depreciation	264
Jacksonville Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,233
Initial Cost, Buildings and Improvements	6,173
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,233
Gross Amount Carried at Close of Period, Buildings and Improvements	6,173
Gross Amount Carried at Close of Period, Total	7,406
Accumulated Depreciation	708
Lafayette Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,819
Initial Cost, Buildings and Improvements	35,424
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	4,819
Gross Amount Carried at Close of Period, Buildings and Improvements	35,424
Gross Amount Carried at Close of Period, Total	40,243
Accumulated Depreciation	3,866
Lakewood Ranch Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	636
Initial Cost, Buildings and Improvements	1,784
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	636
Gross Amount Carried at Close of Period, Buildings and Improvements	1,784
Gross Amount Carried at Close of Period, Total	2,420
Accumulated Depreciation	259
Las Vegas Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	651
Initial Cost, Buildings and Improvements	5,323
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	651
Gross Amount Carried at Close of Period, Buildings and Improvements	5,323
Gross Amount Carried at Close of Period, Total	5,974
Accumulated Depreciation	603
Lehigh Acres Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	441
Initial Cost, Buildings and Improvements	2,956
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	441
Gross Amount Carried at Close of Period, Buildings and Improvements	2,956
Gross Amount Carried at Close of Period, Total	3,397
Accumulated Depreciation	351
Lubbock Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	5,210
Initial Cost, Buildings and Improvements	39,939
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	5,210
Gross Amount Carried at Close of Period, Buildings and Improvements	39,939
Gross Amount Carried at Close of Period, Total	45,149
Accumulated Depreciation	4,282
Manitowoc Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	257
Initial Cost, Buildings and Improvements	1,733
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	257
Gross Amount Carried at Close of Period, Buildings and Improvements	1,733
Gross Amount Carried at Close of Period, Total	1,990
Accumulated Depreciation	242
Manitowoc Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	250
Initial Cost, Buildings and Improvements	11,231
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	250
Gross Amount Carried at Close of Period, Buildings and Improvements	11,231
Gross Amount Carried at Close of Period, Total	11,481
Accumulated Depreciation	1,328
Marinette Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	208
Initial Cost, Buildings and Improvements	1,002
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	208
Gross Amount Carried at Close of Period, Buildings and Improvements	1,002
Gross Amount Carried at Close of Period, Total	1,210
Accumulated Depreciation	144
New Bedford Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,464
Initial Cost, Buildings and Improvements	26,297
Cost Capitalized Subsequent to Acquisition	(27,522)
Gross Amount Carried at Close of Period, Land	115
Gross Amount Carried at Close of Period, Buildings and Improvements	1,124
Gross Amount Carried at Close of Period, Total	1,239
Accumulated Depreciation	32
New Braunfels Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,568
Initial Cost, Buildings and Improvements	11,386
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,568
Gross Amount Carried at Close of Period, Buildings and Improvements	11,386
Gross Amount Carried at Close of Period, Total	13,954
Accumulated Depreciation	1,239
North Smithfield Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,309
Initial Cost, Buildings and Improvements	14,024
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,309
Gross Amount Carried at Close of Period, Buildings and Improvements	14,024
Gross Amount Carried at Close of Period, Total	15,333
Accumulated Depreciation	1,611
Oklahoma City Healthcare Facility IX
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,316
Initial Cost, Buildings and Improvements	9,822
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,316
Gross Amount Carried at Close of Period, Buildings and Improvements	9,822
Gross Amount Carried at Close of Period, Total	11,138
Accumulated Depreciation	1,220
Oshkosh Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	414
Initial Cost, Buildings and Improvements	2,043
Cost Capitalized Subsequent to Acquisition	(1)
Gross Amount Carried at Close of Period, Land	413
Gross Amount Carried at Close of Period, Buildings and Improvements	2,043
Gross Amount Carried at Close of Period, Total	2,456
Accumulated Depreciation	275
Palm Desert Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	582
Initial Cost, Buildings and Improvements	5,927
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	582
Gross Amount Carried at Close of Period, Buildings and Improvements	5,927
Gross Amount Carried at Close of Period, Total	6,509
Accumulated Depreciation	718
Rancho Mirage Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,286
Initial Cost, Buildings and Improvements	5,481
Cost Capitalized Subsequent to Acquisition	(3,767)
Gross Amount Carried at Close of Period, Land	1,227
Gross Amount Carried at Close of Period, Buildings and Improvements	2,773
Gross Amount Carried at Close of Period, Total	4,000
Accumulated Depreciation	0
San Antonio Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,824
Initial Cost, Buildings and Improvements	22,809
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,824
Gross Amount Carried at Close of Period, Buildings and Improvements	22,809
Gross Amount Carried at Close of Period, Total	24,633
Accumulated Depreciation	2,432
San Antonio Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	31,694
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	31,694
Gross Amount Carried at Close of Period, Total	31,694
Accumulated Depreciation	3,379
San Antonio Healthcare Facility V
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,273
Initial Cost, Buildings and Improvements	19,697
Cost Capitalized Subsequent to Acquisition	1,023
Gross Amount Carried at Close of Period, Land	3,273
Gross Amount Carried at Close of Period, Buildings and Improvements	20,720
Gross Amount Carried at Close of Period, Total	23,993
Accumulated Depreciation	2,469
Santa Rosa Beach Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	741
Initial Cost, Buildings and Improvements	3,049
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	741
Gross Amount Carried at Close of Period, Buildings and Improvements	3,049
Gross Amount Carried at Close of Period, Total	3,790
Accumulated Depreciation	326
Savannah Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,300
Initial Cost, Buildings and Improvements	20,186
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,300
Gross Amount Carried at Close of Period, Buildings and Improvements	20,186
Gross Amount Carried at Close of Period, Total	22,486
Accumulated Depreciation	2,168
Sturgeon Bay Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	248
Initial Cost, Buildings and Improvements	700
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	248
Gross Amount Carried at Close of Period, Buildings and Improvements	700
Gross Amount Carried at Close of Period, Total	948
Accumulated Depreciation	111
Victoria Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	328
Initial Cost, Buildings and Improvements	12,908
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	328
Gross Amount Carried at Close of Period, Buildings and Improvements	12,908
Gross Amount Carried at Close of Period, Total	13,236
Accumulated Depreciation	1,414
Victoria Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	446
Initial Cost, Buildings and Improvements	12,986
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	446
Gross Amount Carried at Close of Period, Buildings and Improvements	12,986
Gross Amount Carried at Close of Period, Total	13,432
Accumulated Depreciation	1,409
Wilkes-Barre Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	821
Initial Cost, Buildings and Improvements	4,139
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	821
Gross Amount Carried at Close of Period, Buildings and Improvements	4,139
Gross Amount Carried at Close of Period, Total	4,960
Accumulated Depreciation	509
Yucca Valley Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	901
Initial Cost, Buildings and Improvements	4,788
Cost Capitalized Subsequent to Acquisition	(4,310)
Gross Amount Carried at Close of Period, Land	241
Gross Amount Carried at Close of Period, Buildings and Improvements	1,138
Gross Amount Carried at Close of Period, Total	1,379
Accumulated Depreciation	19
Tucson Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	25,324
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	25,324
Gross Amount Carried at Close of Period, Total	25,324
Accumulated Depreciation	1,735
Tucson Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,763
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	8,177
Gross Amount Carried at Close of Period, Land	1,763
Gross Amount Carried at Close of Period, Buildings and Improvements	8,177
Gross Amount Carried at Close of Period, Total	9,940
Accumulated Depreciation	983
Grimes Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	831
Initial Cost, Buildings and Improvements	3,690
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	831
Gross Amount Carried at Close of Period, Buildings and Improvements	3,690
Gross Amount Carried at Close of Period, Total	4,521
Accumulated Depreciation	417
Tampa Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	10,297
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	10,297
Gross Amount Carried at Close of Period, Total	10,297
Accumulated Depreciation	1,140
Tucson Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	58
Cost Capitalized Subsequent to Acquisition	18,057
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	18,115
Gross Amount Carried at Close of Period, Total	18,115
Accumulated Depreciation	1,289
Greenwood Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,603
Initial Cost, Buildings and Improvements	22,588
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,603
Gross Amount Carried at Close of Period, Buildings and Improvements	22,588
Gross Amount Carried at Close of Period, Total	24,191
Accumulated Depreciation	1,591
Clive Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,555
Initial Cost, Buildings and Improvements	17,898
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,555
Gross Amount Carried at Close of Period, Buildings and Improvements	17,898
Gross Amount Carried at Close of Period, Total	19,453
Accumulated Depreciation	1,073
Clive Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	843
Initial Cost, Buildings and Improvements	12,299
Cost Capitalized Subsequent to Acquisition	57
Gross Amount Carried at Close of Period, Land	843
Gross Amount Carried at Close of Period, Buildings and Improvements	12,356
Gross Amount Carried at Close of Period, Total	13,199
Accumulated Depreciation	634
Clive Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	720
Initial Cost, Buildings and Improvements	7,863
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	720
Gross Amount Carried at Close of Period, Buildings and Improvements	7,863
Gross Amount Carried at Close of Period, Total	8,583
Accumulated Depreciation	499
Clive Undeveloped Land
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,061
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,061
Gross Amount Carried at Close of Period, Buildings and Improvements	0
Gross Amount Carried at Close of Period, Total	1,061
Accumulated Depreciation	0
Clive Undeveloped Land II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	460
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	460
Gross Amount Carried at Close of Period, Buildings and Improvements	0
Gross Amount Carried at Close of Period, Total	460
Accumulated Depreciation	0
Yukon Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,288
Initial Cost, Buildings and Improvements	16,779
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,288
Gross Amount Carried at Close of Period, Buildings and Improvements	16,779
Gross Amount Carried at Close of Period, Total	18,067
Accumulated Depreciation	835
Burr Ridge Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	922
Initial Cost, Buildings and Improvements	12,905
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	922
Gross Amount Carried at Close of Period, Buildings and Improvements	12,905
Gross Amount Carried at Close of Period, Total	13,827
Accumulated Depreciation	701
Prosser Healthcare Facility I
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	282
Initial Cost, Buildings and Improvements	1,933
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	282
Gross Amount Carried at Close of Period, Buildings and Improvements	1,933
Gross Amount Carried at Close of Period, Total	2,215
Accumulated Depreciation	105
Prosser Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	95
Initial Cost, Buildings and Improvements	3,374
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	95
Gross Amount Carried at Close of Period, Buildings and Improvements	3,374
Gross Amount Carried at Close of Period, Total	3,469
Accumulated Depreciation	176
Prosser Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	59
Initial Cost, Buildings and Improvements	2,070
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	59
Gross Amount Carried at Close of Period, Buildings and Improvements	2,070
Gross Amount Carried at Close of Period, Total	2,129
Accumulated Depreciation	107
Tampa Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	47,042
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	47,042
Gross Amount Carried at Close of Period, Total	47,042
Accumulated Depreciation	1,821
Escondido Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	57,675
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	57,675
Gross Amount Carried at Close of Period, Total	57,675
Accumulated Depreciation	2,163
West Palm Beach Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,064
Initial Cost, Buildings and Improvements	7,011
Cost Capitalized Subsequent to Acquisition	30
Gross Amount Carried at Close of Period, Land	2,065
Gross Amount Carried at Close of Period, Buildings and Improvements	7,040
Gross Amount Carried at Close of Period, Total	9,105
Accumulated Depreciation	107
Burr Ridge Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,828
Initial Cost, Buildings and Improvements	46,152
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	4,828
Gross Amount Carried at Close of Period, Buildings and Improvements	46,152
Gross Amount Carried at Close of Period, Total	50,980
Accumulated Depreciation	$ 387

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - NARRATIVE) (Details)	Dec. 31, 2023 USD ($) property	Dec. 31, 2022 USD ($)
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Number of properties collateralized under line of credit facility \| property	111
Total credit facility, principal amount outstanding	$ 525,000,000	$ 583,000,000
Aggregated cost for federal income tax purposes	$ 2,011,524,000
Minimum
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Life used for depreciation	15 years
Maximum
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Life used for depreciation	40 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column B
-Publisher SEC

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column C
-Publisher SEC

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column D
-Publisher SEC

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column E
-Publisher SEC

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column F
-Publisher SEC

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column G
-Publisher SEC

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column H
-Publisher SEC

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Paragraph Column I
-Publisher SEC

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 28
-Footnote 2
-Publisher SEC

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column F))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column D))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column C))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column I))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 970
-SubTopic 360
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-28(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1

+ Details

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - ROLLFORWARD) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward]
Balance at beginning of year	$ 2,089,200	$ 2,015,330	$ 2,890,958
Acquisitions	60,055	144,424	66,890
Improvements	1,727	4,735	23,288
Other adjustments	0	182	978
Impairment	(28,651)	(53,230)	(29,673)
Dispositions	(266,523)	(22,241)	(936,594)
Other adjustments	0	0	(517)
Balance at end of year	1,855,808	2,089,200	2,015,330
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]
Balance at beginning of year	(209,118)	(165,784)	(197,134)
Depreciation	(52,404)	(51,584)	(56,999)
Impairment	8,409	8,250	2,507
Dispositions	25,957	0	85,325
Other adjustments	0	0	517
Balance at end of year	$ (227,156)	$ (209,118)	$ (165,784)